Two patients. Two treatment teams. Two unique conversations.
The vital contribution that basic science research makes to the improvement of treatment for people with cancer is at the heart of Memorial Sloan-Kettering’s mission.

In our 2008 Annual Report you are invited to sit in on two unique conversations. In one, a patient — and in the other, the parents of a pediatric patient — participate in roundtable discussions with the scientists whose laboratory investigations led to the development of agents that made significant contributions to each patient’s survival. These roundtables also included the patients’ MSKCC treatment teams.

Both patients endured arduous and complex treatment journeys — and both benefited from the innovative research conducted at MSKCC as well as from the expertise, creativity, and dedication of their physicians and nurses.

The occasion of our Annual Report provided an opportunity for these exceptional gatherings, allowing us to give you a glimpse into the collaborative and novel work being done every day at the Center and into the lives of two extraordinary people — Emily Wang and James Creaby.
A roundtable conversation with Emily Wang’s parents and her neuroblastoma treatment team

Pages 8 - 27
While the economic crisis that has affected our nation has also had effects on Memorial Sloan-Kettering Cancer Center, 2008 was nevertheless a year in which we continued to excel in all three of our missions—clinical care, research, and training. Although obliged to anticipate additional effects of the economic downturn in 2009 and beyond, years of strategic planning along with disciplined financial and operational management have put us in good stead for the future.

Before going into detail about how MSKCC is faring now—and how we will address the challenges sure to confront us in the coming years—we want to share some highlights from our continuing record of accomplishment:

- We received high scores and a healthy budgetary increase during the competitive renewal of our Comprehensive Cancer Center grant from the National Cancer Institute.
- The Joint Commission renewed our hospital accreditation with a remarkably small number of recommendations, a tribute to the quality of our clinical staff and its operations.
- Enrollment continued to grow in our graduate training programs, including the new Gerstner Sloan-Kettering Graduate School of Biomedical Sciences—which has now been officially accredited by New York State.
- At a time of limited support from the National Institutes of Health, our philanthropically based research efforts—the Geoffrey Beene Cancer Research Center, the Starr Cancer Consortium, the Experimental Therapeutics Center, the Brain Tumor Center, and others—have flourished.
- Our laboratory and clinical investigators put in especially strong performances and received several notable honors.
- And we successfully recruited outstanding new people to our administrative, clinical, and laboratory staffs.
Programs and Initiatives

Ensuring exceptional care for our patients is a primary goal at Memorial Sloan-Kettering. The staff of Memorial Hospital maintained their extraordinary commitment to service, teamwork, and overall excellence throughout 2008.

Our research enterprise remained strong throughout 2008, and we continued to produce new knowledge about the causes of cancer, to strengthen ties between basic science and clinical applications, and to recruit outstanding research faculty members.

In May, the Geoffrey Beene Cancer Research Center sponsored a two-day retreat that brought together members of MSKCC’s Cancer Biology and Genetics Program and its Human Oncology and Pathogenesis Program. Panels featured a variety of topics including cancer metastasis, signaling pathways, and novel targets for cancer therapeutics. In addition, poster sessions allowed graduate students and postdoctoral fellows the opportunity to present and discuss their latest research projects.

In September, 40 Memorial Sloan-Kettering researchers gathered with scientists from four other institutions for a two-day retreat to present and discuss projects funded by the Starr Cancer Consortium. The Consortium, funded by a $100 million gift from the Starr Foundation, is a collaboration among MSKCC, the Broad Institute of MIT and Harvard, Cold Spring Harbor Laboratory, The Rockefeller University, and Weill Cornell Medical College. It provides a framework for joint projects that harness the complementary strengths of the five institutions to improve the understanding, diagnosis, and treatment of cancer.

The creation in 2008 of the Cell Therapy and Cell Engineering Facility provides support to MSKCC investigators conducting early-stage clinical trials that require biological materials for immunotherapies, vaccines, and stem-cell-based therapies.

At Memorial Sloan-Kettering, we seek to educate and inspire future scientists and clinicians by fostering an enthusiasm for science and medicine. Our third annual Major Trends in Modern Cancer Research seminar drew approximately 460 high school students from about 60 schools in the New York City area to hear three leading MSKCC scientists present their work and explain how developments in their areas of expertise are contributing to a better understanding of cancer.

Our second annual Postdoctoral Research Symposium gave MSKCC’s postdoctoral fellows an opportunity to share their latest findings with Center colleagues, mentors, and members of the Tri-Institutional community, which also includes The Rockefeller University and Weill Cornell Medical College. More than 80 scientific projects were described through oral presentations and poster discussions at the daylong event.

Finally, we were honored to have New York State Governor David A. Paterson address our 29th annual Academic Convocation.

Honors

In 2008, three of MSKCC’s most distinguished scientists were elected members of the Institute of Medicine (IOM) of the National Academies: Kathryn V. Anderson, Chair the Developmental Biology Program in the Sloan-Kettering Institute; Charles L. Sawyers, Chair of the Human Oncology and Pathogenesis Program within Memorial Hospital; and James P. Allison, Chair of SKI’s Immunology Program. Membership in the IOM is considered one of the highest honors in the fields of health and medicine.

In addition, Sloan-Kettering Institute Director Thomas J. Kelly was named a member of the Advisory Committee to the Director (ACD) at the National Institutes of Health. The ACD was created in 1966 to advise the NIH director on policy and planning issues important to the NIH mission.
Philanthropy

It was another strong year for the Campaign for Memorial Sloan-Kettering, which has generated more than $1.82 billion in gifts and pledges over the past seven years and is closing in on its $2 billion goal. Despite mounting economic uncertainty during the course of 2008, the Center had the best fundraising year in its history, recording a total of $315.4 million in philanthropic income. We expect 2009 to be a challenging year and are intensifying efforts to attract the gift support that has become so important.

Under the leadership of Society President Leslie Jones, the members of The Society of MSKCC continue to work to help Center patients, raise funds, and increase public awareness of cancer. (To learn more about the activities of The Society of MSKCC, please see page 80.)

Current Economic Realities, Future Effects

Naturally, we are troubled by the current economic crisis. But we are responding to it vigorously and are confident that the Center will remain strong and weather the storm.

We are proud to have operated the institution well, and in a fiscally responsible manner; as a result, our performance in 2008 was strong. Our clinical volumes met our expectations, income from operations was slightly improved when compared to 2007, and the Center continues to generate operating revenues in excess of its expenses.

However, the crisis in the financial markets has had an adverse impact on our long-term investments. Although we do not yet have final results for our non-marketable securities, we expect the total loss for the entire portfolio will be approximately 28 percent. Consequently, our ability to use income from our investments to support our operating and capital needs will be less than it has been in the past. While that income represents a relatively small percentage of the Center’s overall revenue, budgets will need to be adjusted accordingly in the future until our endowment regrows.

In addition, our major source of revenue, payments for health care, may be less reliable in the coming year, due to the general downturn in the economy. For example, we anticipate several million dollars less in Medicaid reimbursements and, with many more people unable to pay their bills, we can expect to deliver a higher level of charity care than usual. Moreover, we cannot predict whether demands for our services will remain at their current high level. And we will face challenges in securing philanthropic support.

To manage this financial situation, Center leadership is redoing future plans for capital expenditures and moderating expense growth. We are looking in all areas of the institution to reduce expenses.

We have modified some of our construction plans for the coming year. Our new 16-story Breast and Imaging Center on Second Avenue between 65th and 66th Streets, which contains the expanded Evelyn H. Lauder Breast Center, will open to receive outpatients in the fall of 2009. While we will finish 11 floors, we will slow the completion of the remaining five floors, which are planned to be used as academic space at a later time. The second phase of the Mortimer B. Zuckerman Research Center (ZRC)—a seven-story structure on East 68th Street that will complete the ZRC complex—advanced steadily throughout 2008. Installation of the exterior building walls began in November and will continue through late spring of 2009. We will then defer finishing the interior and will resume the project when economic conditions improve.
We will maintain our recruitment efforts but will exercise restraint, particularly when considering empty positions not deemed critically important; and, while institutional funds will continue to be used to support laboratory and clinical research activities so that these will move forward with minimal disruption, we will—as we always have—focus on optimizing our resources and scrupulously controlling costs. By taking these steps, we expect to remain in a comparatively favorable fiscal condition.

Memorial Sloan-Kettering represents the best our society can offer to those who suffer from cancer. Over the next year or two, we may move ahead more slowly than any of us would like toward the goal of building a still-better institution. However, we will proceed with our commitments to clinical care, research, and training not simply intact, but robust and thriving.

MSKCC’s achievements are made possible by many people. Our success as an institution is due in great measure to the expertise of our remarkable staff. We are grateful to them for their work, and know that they will continue to serve our patients and this institution with energy, dedication, and imagination through these difficult times. MSKCC’s Executive Vice President John R. Gunn and Senior Vice President of Finance Michael P. Gutnick play key roles in maintaining the Center’s financial stability. Memorial Hospital Physician-in-Chief Robert E. Witten and Senior Vice President and Hospital Administrator Kathryn Martin are vital in guiding our clinical programs, maintaining a high level of patient satisfaction, and fostering constant improvements. Director of the Sloan-Kettering Institute Thomas J. Kelly continues to lead our research programs with intelligence and skill.

We also note with sorrow the death of surgical and molecular pathologist William L. Gerald. As Director of the Pathology Research Core Facility, Dr. Gerald built one of the largest research tumor banks in the nation. He was one of the founding members of the Center’s Human Oncology and Pathogenesis Program and made major contributions to the understanding of cancer, in particular, prostate and breast cancer, the desmoplastic small round cell tumor, and neuroblastoma. His insight and intelligence are profoundly missed.

In this year’s report we invite you to sit in on two exceptional roundtable discussions. In one, a patient—and in the other, the parents of a patient—talk with the scientists whose research led to the development of agents that made a significant contribution to each patient’s survival. These discussions, which also include members of the MSKCC teams that treated these two patients, offer a compelling look at the innovative work being done every day at Memorial Sloan-Kettering. We hope that they will describe to you the pride we take in this institution and our unwavering commitment to excellence.

Douglas A. Warner III
Chairman, Boards of Overseers and Managers

Harold Varmus
President
Emily Wang
PATIENT
In 2003, just before her second birthday, Emily Wang was diagnosed with a rare pediatric cancer called neuroblastoma. Approximately 750 children a year in the United States are diagnosed with the disease—a cancer of the sympathetic nervous system. Emily’s treatment extended over several years and included two novel immunotherapies conceived and developed by pediatric oncologist Nai-Kong Cheung, head of MSKCC’s neuroblastoma program, and his colleagues in the neuroblastoma laboratory. What follows is a conversation between Emily’s parents and the members of the neuroblastoma treatment team.

meet

Emily Wang was diagnosed with neuroblastoma in 2003.
Kim Kramer
PEDIATRIC ONCOLOGIST

Michael La Quaglia
CHIEF, PEDIATRIC SURGICAL SERVICE

Mark Souweidane
PEDIATRIC NEUROSURGEON

Charles Sklar
PEDIATRIC ENDOCRINOLOGIST, DIRECTOR, LONG-TERM FOLLOW-UP PROGRAM

Tina and Richard Wang,
Emily and her brother, Ryan
PATIENT’S FAMILY
It was the end of June, and my mom was the first to notice that Emily’s stomach was distended. But two-year-olds have potbellies so I didn’t think much of it. Then she started running a low-grade fever, and on the July Fourth weekend she got very cranky.

We had a little backyard pool for the kids, and Emily loved it. But suddenly she wouldn’t go near the water.
The blood work came back, and she was extremely anemic. The pediatrician reexamined her — this time he brought in his partner. Even then, we were hoping it was something minor.

MR. WANG

One of the keys to survival in Stage 4 neuroblastoma is that the tumor must be completely removed. Otherwise, it’s going to come back.

DR. CHEUNG

She just wanted me to hold her.

MRS. WANG

We recognized something was really wrong.

MR. WANG

That Monday we took her to the pediatrician. He examined her and said she was constipated — but I knew she wasn’t. So he did some blood work.

MR. WANG

The blood work came back, and she was extremely anemic. The pediatrician reexamined her — this time he brought in his partner.

MRS. WANG

They told us they felt something in her abdomen and said, “You need to bring her to the ER right away for a sonogram.”

MRS. WANG

Even then, we were hoping it was something minor.

MR. WANG

But in the ER the technician asked me, “Does she have a mass on her kidney?” and I said, “No, she wasn’t born with any mass on her kidney.” And he said, “Well, she has one now.”

MR. WANG

The doctors told us it was most likely Wilms’ tumor [the most common cancer of the kidneys found in children].

MRS. WANG

But I saw in their eyes, Rich, that it was probably something even worse. It was the most horrible day of our lives.

Two days later, the Wangs transferred Emily to Morgan Stanley Children’s Hospital of NewYork-Presbyterian/ Columbia University Medical Center. A biopsy revealed that the mass was not Wilms’ but Stage 4 neuroblastoma. Shortly thereafter, the Wangs scheduled an appointment at MSKCC. The first member of the neuroblastoma team they met with was Shakeel Modak.

We went through the plan of action — and there are several things that are unique here. First, we have a highly experienced surgeon, Michael La Quaglia, who does lots of neuroblastoma surgeries.

NAI-KONG CHEUNG

One of the keys to survival in Stage 4 neuroblastoma is that all the visible tumor must be completely removed.

DR. MODAK

We also have a very strong program in immunotherapy. Using antibodies, we try to maintain remissions in children.

As part of what is called the N8 protocol — which includes chemotherapy, surgery, radiation, a stem cell transplant, and treatment with a monoclonal antibody — Emily first underwent induction. Induction is chemotherapy designed to stop the growth of the cancer and shrink the tumor so that surgery can be more safely performed.

DR. CHEUNG

Emily had five rounds of induction chemotherapy on the N8 protocol. Historically, six or seven rounds have been used, but our research shows that the outcome is as good with five rounds — and we think we can cut back even more. There are patients who will go into remission sooner and probably don’t need that fifth cycle. By cutting back, you hope to minimize the long-term side effects. Dose intensity is critical — meaning that you give the same total dose but over three months instead of six, and you get a much better result.
There are several challenges in removing these tumors. First, they usually grow close to the big blood vessels of the body—the aorta and the vena cava. So even though the tumor itself may be less vascular, you still need to control bleeding. We also don’t routinely sacrifice a kidney; rather, we’re very aggressive in trying to save the kidney. Over time, we’ve developed techniques to deal with both of these issues. We’re able to successfully remove more than 95 percent of these tumors, and our mortality rate is well below 5 percent—and this is extremely serious surgery.

In Emily’s case, Dr. La Quaglia removed the outer and inner linings of the kidney to expose the blood vessels.

If you try to do surgery before chemotherapy you can get a lot of bleeding. There’s good data showing that overall survival is the same if you delay surgery until after giving chemotherapy.

The tumor involved the artery and the veins in Emily’s kidney, so we had to remove the tumor from around them. It was really a vascular dissection. A surgical oncologist who does this kind of operation needs to have expertise in many surgical specialties because the techniques we use run the gamut—from vascular to chest to abdominal surgery.
A vital component of pediatric cancer surgery is the contribution of the anesthesiologist.

We have excellent anesthesiologists at Memorial. They understand how to manage kids getting big tumor operations. A child's physiology can cause his or her blood pressure to drop quickly and suddenly. You need an anesthesiologist expert in recognizing when and how to replace blood and fluids. In all ways, what we do here is a team effort. It doesn’t happen just because of surgery or radiation or chemotherapy. It happens because we put it all together.

Emily was next referred to me for radiation therapy. We’ve learned that giving low-dose radiation after surgery to the site of the primary tumor and the lymph nodes in the abdomen decreases the chance of a relapse to approximately 10 percent. We used three-dimensional CT planning to design treatment fields that minimized the dose to her healthy tissues, including her kidneys and liver, and to avoid her ovaries.

By giving radiation twice a day, we can use lower doses. It also means that treatment can be accomplished quickly — over seven to ten days. But it is impossible for these very young children to stay perfectly still for our high-precision radiation treatment, so we need to anesthetize them. Again, we couldn’t do this if we didn’t have an anesthesia team experienced in giving sleep medication to children during radiation.

The hardest part of it was that because of the anesthesia, Emily couldn’t eat or drink until later in the day, after the second treatment.

There’s no question that while it’s only a week and a half it’s difficult for the child and the parents.
We provide every resource we can to help children use what is within them to deal with the stress of this illness and its treatment. We’re concerned with the entire child, not just the disease.

DR. CHEUNG

We’ve learned that giving low-dose radiation after surgery to the site of the primary tumor and the lymph nodes in the abdomen decreases the chance of a relapse to approximately 10 percent.

DR. WOLDEN
Two decades ago you wanted to cure just one kid, and you couldn’t. And today, if we don’t achieve a cure we ask, “What went wrong?” That’s a huge evolution.

DR. KUSHNER
The next phase of Emily’s treatment involved the addition of a novel immunotherapy called 3F8, a monoclonal antibody developed by Dr. Cheung and his colleagues. 3F8 antibodies seek out and attach to neuroblastoma cells, signaling the immune system to destroy them.

To learn more about 3F8 and 8h9, the second antibody with which Emily was treated, see the sidebar on the next page.

We know that 3F8 targets very well to neuroblastoma tumor cells. But there is one big side effect — pain. Two decades ago, when we first gave it to children and saw that they had pain, we actually stopped for a year and went back to the lab to try to understand what was going on. We discovered that when 3F8 attaches to GD2 (a sugar lipid that is abundant on neuroblastoma cells and also present on some nerve cells), a message is sent to the brain and the patient feels pain.

You warned us that it was going to be painful, and it was. The first time Emily got 3F8 her body suddenly stiffened, and she began screaming at the top of her lungs. All we could do was cradle her. Then the nurse gave her pain medication and slowly it subsided. We also learned from the nurses how to put hot packs on her, how to massage her legs and her belly.

We really have to say how amazing all the nurses were. They were there to help us every step of the way.

And after Emily had had a number of cycles, they brought in a dance therapist to see if she could help. When Emily got the 3F8 usually the pain would come about 20 minutes later. But when Suzi danced with her, the pain never came.

We provide every resource we can to help children use what is within them to deal with the stress of this illness and its treatment. We’re concerned with the entire child, not just the disease.

A stem cell transplant was next in the protocol. Emily was admitted to the hospital and put in isolation as she underwent a preparative regimen of chemotherapy to destroy her bone marrow.
marrow and any remaining cancerous cells. The high-dose chemotherapy that destroys the bone marrow also cripples the body’s immune system. Everyone who has contact with such patients must be gowned, masked, and gloved. Until the healthy transplanted stem cells are infused and are engrafted patients are extremely susceptible to infection.

Mrs. Wang It was 29 days exactly. We counted.

Mr. Wang And even though Emily didn’t feel well she was a real trouper.

Mrs. Wang She had tea parties with her stuffed animals. She watched her favorite videos. No matter how hard it was, she got out of bed every morning to try to enjoy herself like a regular three-year-old. She got us through it.

Mr. Wang I remember the day Dr. Boulad injected the stem cells. [Farid Boulad is the Director of MSKCC’s Pediatric Day Hospital and a member of the Bone Marrow Transplant Service.] It was the Chinese New Year.

Emily’s stem cell transplant was successful. 3F8 immunotherapy was resumed and differentiation therapy was instituted to halt the growth and spread of any remaining neuroblastoma cells. Differentiation therapy is an approximately six-month course of oral medication known as 13-cis-retinoic acid (Accutane®). The same medication that is sometimes used to treat severe acne, it also encourages immature neuroblastoma cells to stop dividing. Emily was within days of completing her entire course of treatment when, in March 2005, came a devastating turn of events.

Antibodies are proteins that help the immune system identify foreign substances by binding to them and marking them for removal. However, because cancer—including neuroblastoma—arises from the normal tissues of the body, the immune system usually does not recognize cancer cells as foreign; or if it does, is unable to mount a strong and sustained attack.

3F8 is a monoclonal antibody. Conceived and developed by Nai-Kong Cheung and his colleagues in the neuroblastoma laboratory, 3F8 is a treatment that is injected into the bloodstream where it travels through the body until it finds and attaches to a marker called GD2 present on all neuroblastoma cells. When it does so, this signals the patient’s immune system to recognize neuroblastoma cells as foreign and to attack and kill those cells.

Until recently, 3F8 was available only to patients at MSKCC. It has now been licensed to an outside company, and a randomized clinical trial is scheduled to begin at several institutions nationwide.

8H9 is a newer monoclonal antibody also developed by Dr. Cheung. It is being used at MSKCC to target neuroblastoma cells that have metastasized to the brain. 8H9 is linked to radioactive iodine and infused directly into the cerebrospinal fluid. It is currently in clinical trials at the Center, and approximately three-quarters of neuroblastoma patients who have received the treatment are doing well up to five years later.
We were in the last cycle of Accutane. Suddenly Emily began throwing up, and pretty soon she became lethargic, almost unresponsive. So we raced her to the hospital. Kim, you were there.

The minute you saw us you knew something was seriously wrong.

I did. The neuroblastoma had spread to her brain. In this whole journey I think that was the hardest day for everyone. You just feel like the rug’s been pulled out from under you.

As a team, we were devastated.

We were in the last cycle of Accutane. Suddenly Emily began throwing up, and pretty soon she became lethargic, almost unresponsive. So we raced her to the hospital. Kim, you were there.

The minute you saw us you knew something was seriously wrong.

I did. The neuroblastoma had spread to her brain. In this whole journey I think that was the hardest day for everyone. You just feel like the rug’s been pulled out from under you.

As a team, we were devastated.

But at the same time, we rallied, regrouped immediately, and sat down to discuss the new plan.

I remember I thought, "This is the end." But you all said, "There’s a new treatment — we’re going to get her back into remission."

This was a problem we did not anticipate because in the past we were not yet good enough at controlling the disease in the rest of the body. But now children are surviving at a much higher rate — the long-term survival rate of patients treated with 3F8 is better than 50 percent — and we’re seeing this new pattern of relapse. It is like another mountain behind the mountain.

Up until 8H9, which we developed within the past five or six years, a child like Emily wouldn’t have survived. But that’s the great thing about working at Memorial: We’re not here just to dish out treatments — we’re here to study the disease and come up with better therapies.

The tumor was in the left temporal region. Taking these tumors out is a very delicate proposition. This is an area that’s responsible for speech and language. Also, metastatic neuroblastoma lesions tend to grow around the brain’s major blood vessels and can bleed quite readily. But Emily came through the operation remarkably well and was discharged after only a couple of days in the hospital.

I then saw her again for additional radiation therapy. Because neuroblastoma cells can travel through the cerebrospinal fluid and “seed” elsewhere, we use a technique called craniospinal radiation to deliver radiation to the entire brain and spine to try to get every neuroblastoma cell that might be floating around. It’s a very complex and technically difficult treatment requiring millimeter accuracy. Our treatment planning and all our technology are highly dependent on medical physics — and we have one of the best teams in the nation. We collaborate very closely with the physicists in planning and in evaluating radiation doses. We also rely on our colleagues in diagnostic radiology to provide us with the images we need for treatment planning and in the evaluation of those images.

After Emily’s craniospinal radiation was complete, Dr. Souweidane implanted a catheter into Emily’s brain through which the 8H9 antibodies would be delivered.
The 8H9 antibodies are infused into the cerebrospinal fluid, so I implanted a port under Emily’s scalp with a catheter that I threaded into one of the ventricles in her brain. This allowed the injection of the therapeutic antibodies directly into the brain through a simple needle stick to the port.

We arm 8H9 with radioactive iodine and use it as a radiation delivery system—we’re actually bathing the cerebrospinal fluid in liquid radiation. Again, it’s important to point out that this is a multidisciplinary effort. We depend on our radiochemist [Peter Smith-Jones], medical physicists [John Humm and Pat Zanzonico], and the nuclear medicine team [Steven Larson, Chief of the Nuclear Medicine Service; Neeta Pandit-Taskar; and Jorge Carrasquillo] to tell us exactly how much radiation is going to different parts of the brain and how long it’s staying there.

Dr. Larson has collaborated with us over the past 20 years in looking at how radiolabeled antibodies like 8H9 target human tumors. We now use PET imaging to tell us precisely where the antibody is going and how much of the dose is getting to the tumor.

The 8H9 was much easier than the 3F8. Emily went through the treatments like they weren’t anything.

We were the ones who were nervous. A team of eight or nine people descend on this kid and she can’t see what’s going on behind her—

Well, she did say, “What are they doing to my head?!?”

[Laughter]

Emily was the first female patient to receive 8H9, and only the third patient on this regimen. Sixteen neuroblastoma patients have now been similarly treated, and we’re using it in other types of tumors.

Certain sarcomas affect the abdomen, and we’re trying to use the antibody there. And Dr. Kramer is also starting to evaluate it in other types of brain tumors.

We’re always working on the next step so that we have something new up our sleeves to give children who may need it a second, a third, or even a fourth chance.

My personal goal 20 years ago was that if we could cure one child it would be amazing. Then we woke up one day and suddenly realized we expected cures. So two decades ago you wanted to cure just one kid, and you couldn’t. And today, if we don’t achieve a cure we ask, “What went wrong?” That’s a huge evolution.
These children are all pioneers. They’ve been to the mountaintop and have come back to tell us what it was like and what we should do.

There came a point where we didn’t want to stop seeing all of you.

You became like our family.

I think Emily may have been more comfortable here than being forced to go to school! [Laughter] By the way, I expected to see her today. Where is she?

In school — but she wanted to come! Emily will always remember being sick, but she doesn’t see herself as anything except normal. She’s just like other kids, and nobody can take advantage of her.

And she makes sure everybody knows it!

Emily Wang, now seven, is thriving. The only long-term side effects of treatment so far are her small stature, some high-frequency hearing loss, and an underactive thyroid. She is followed by members of the neuroblastoma treatment team as well as by Charles Sklar, Director of MSKCC’s Long-Term Follow-Up Program, and members of his team. To read more about that program, please see page 26. Dr. Cheung and the neuroblastoma team continue to investigate new antibodies to improve outcomes for patients.

MSKCC radiologists Sara Abramson and Anita Price and the members of the Department of Clinical Laboratories made significant contributions to Emily Wang’s treatment and continue to collaborate with the neuroblastoma team in the treatment of other patients. The late MSKCC surgical and molecular pathologist William Gerald also made major contributions to ongoing research and understanding of the disease.
Dedicated nurses and social workers play a central role in the care of children and families going through treatment for neuroblastoma. Here are their voices as they talk about Emily Wang; parents, Tina and Richard; and the journey they all took together. They also share their thoughts on families coping with cancer and their own roles as specialists in pediatric oncology at MSKCC.

My main role was caring for Emily through her 3F8 antibody treatment. These treatments are painful, and they’re hard on the parents and the children. At the time, Emily wasn’t talking much, but she started calling me “Jie-Jie.” I didn’t know at first what it meant, but I found out that Jie-Jie means “older sister” in Chinese and that her grandmother was teaching her to call me Older Sister.

MS. ENERO

We have children like Emily who have had CNS relapses. Just a few years ago that would have been fatal. Now three or four years later, we’re watching them get their brown belt in karate, finish kindergarten, go into the first grade, have their first communion. We’ve come so far.

MS. TOMLINSON

I was here the day Emily’s parents brought her in with her CNS [central nervous system] relapse. She was draped in her father’s arms, completely listless. I had a terrible feeling in the pit of my stomach. Her parents were beyond devastated. My heart bled for them. I’ll never forget that day.

MS. D’ANDREA
People allow you into their lives at their most vulnerable point, and you get to know them in a way you might not know your own neighbors or maybe even your own family. It’s very intimate, and it’s a privilege to participate in pediatric oncology here at Memorial.

Ms. Lin

We have different nationalities, different socioeconomic classes, and yet everyone reaches out to everyone else. Everyone understands there’s no right or wrong way to get through this kind of experience.

Ms. Iannuzzi

I’ve been at Memorial for more than 30 years. I was in Pediatrics for nine years, then left to set up an oncology service in a community hospital. But I returned. I missed the connections you form in Pediatrics with the children, their families, and your colleagues. When I came back, it was like coming home.

Ms. Dantis
Emily Wang is seen every six months by Dr. Sklar, director of the program and a pediatrician specializing in endocrinology. Her treatment for neuroblastoma has given rise to several medical issues for which she is monitored by Dr. Sklar and the two nurse practitioners on his team. “Emily has short stature, an underactive thyroid gland, and hearing loss,” Dr. Sklar says. “These are common in children who have undergone treatments similar to hers.” Treatment-related long-term side effects (also called late effects) are generally correlated with specific therapies, explains Dr. Sklar. Children treated with similar therapies will be at risk for similar problems regardless of their diagnosis.

In the course of her treatment, Emily received chemotherapy as well as radiation therapy to her abdomen, spine, and brain. “The problems that she has are most likely due to the radiation, although her hearing loss may be related to the chemotherapy,” Dr. Sklar says. If children receive radiation to the brain early in life they are at risk for cognitive disabilities, growth problems, and especially for very young girls, early puberty.

“You’re radiating the brain at a time when it’s still developing,” Dr. Sklar explains. “For example, the brain has the capacity to send one into puberty at any age. However, there are central nervous system restraining mechanisms that tell the hypothalamus and the pituitary gland, ‘Don’t start puberty yet.’ But various insults — including head trauma, infection to the brain, and radiation — may damage these inhibitory signals, and the brain can send the body into puberty prematurely.” (As of now, Emily shows no signs of early puberty.)

The Long-Term Follow-Up Program team sees approximately 80 to 100 patients a month. Eighty percent of the program’s patients were treated at MSKCC, and about 20 percent were treated elsewhere. “When we see children for the first time we develop a care plan based on their past treatments and their age at the time they were treated,” says Dr. Sklar.

This individual plan details the tests that should be done to monitor for specific problems and the frequency with which they should be performed. “There are many things we can do to treat conditions before they cause symptoms,” Dr. Sklar elaborates. “For instance, Emily is on thyroid medication, and her thyroid levels are now normal. If you wait for someone to become symptomatic it could take months to years and damage may already have been done.”

Children who face growth and development problems may require hormonal therapies; learning and cognition difficulties can often be addressed with special schooling arrangements; cardiac complications, while less common, may be helped with certain medications; and patients at high risk for secondary cancers can be more rigorously screened throughout life.

Dr. Sklar points out that even if early interventions cannot entirely do away with all medical problems, simply knowing what to expect can help to mitigate the effects of coping with them. “A child with cancer is a family with a child with cancer — these are family issues. If everybody is aware of potential problems from the outset; it won’t necessarily neutralize them, but it can help in the psychological adjustment.” Dr. Sklar goes on to observe that the Long-Term Follow-Up Program provides a resource that offers families great comfort. “We’re experts in what they and their child have been through,” he says.

Dr. Sklar also collaborates closely with his colleagues in the Department of Pediatrics. “I need to know what the treatments are and how they’re evolving because I’m going to be seeing these kids down the line,” he comments. “And my colleagues often discuss with me what sort of late effects a child may suffer as a result of a particular form of therapy. We meet every week as a department. There’s a tremendous amount of give-and-take. They learn from me and I learn from them.”

As children in the Long-Term Follow-Up Program reach their late teens and early 20s, they transition into MSKCC’s Program for Adult Survivors of Pediatric Cancer, led by Kevin Oeffinger. “There are very few institutions in the world that offer this kind of continuum of care,” says Dr. Sklar. “We’re very fortunate to have these truly comprehensive, ongoing programs.”

Established in 1990 by MSKCC’s Department of Pediatrics, the Long-Term Follow-Up Program, led by Charles Sklar, helps children and families manage the chronic medical conditions that may often develop after treatment for cancer.
Jianda Yuan
IMMUNOLOGIST,
HEAD, IMMUNE MONITORING
CORE FACILITY

Jedd Wolchok
MEDICAL ONCOLOGIST

James Allison
CHAIR, IMMUNOLOGY
PROGRAM

James Creaby
PATIENT
In 1999, James Creaby — then 51 and a foreign exchange currency trader with Morgan Guaranty — was diagnosed with melanoma, the most serious form of skin cancer. Thus began a journey studded with numerous recurrences and remissions that continues to the present day. He is currently being treated at Memorial Sloan-Kettering with an innovative immunotherapy discovered and developed by James Allison, Chair of Sloan-Kettering Institute’s Immunology Program. Mr. Creaby recently sat down with his physician Jedd Wolchok, Dr. Allison, and Jianda Yuan, head of MSKCC’s Immune Monitoring Core Facility, to talk about the arduous and complex path of his therapy.
I first knew something wasn’t right when a mole about the size of a pencil eraser appeared on my right side around the area of my ribs. My wife, Jane, said “Let’s get that checked, Jim.” But they run in my family, and I was sure it was nothing. So it wasn’t until about eight months later that I finally went to a dermatologist. He removed the mole, and two days after that we got a call asking us to come to his office — where he told us it was melanoma.

Mr. Creaby underwent surgery to remove skin surrounding the melanoma in order to reduce the risk of recurrence. At the time of surgery, a biopsy showed that the sentinel lymph node under his right arm contained a few melanoma cells. The sentinel node is the first lymph node to which cancer cells are likely to spread from a primary tumor. Subsequent surgery to remove all the remaining underarm nodes showed no further spread of the disease.
JEDD WOLCHOK

In most patients with Stage 3 melanoma there is about a 50-50 chance of melanoma coming back. Some people are at higher risk and some at lower, but generally that’s the reality.

DR. WOLCHOK

In most patients with Stage 3 melanoma there is about a 50-50 chance of melanoma coming back. It required infusions five days a week for a month, during which I’d have to stay home, unable to work — and then I’d have to inject myself three times a week for the next 11 months. When I learned that there was already a 50-50 chance that the melanoma would come back anyway — and that interferon would only increase the odds of it not returning by an additional 10 percent — I decided to forgo the injections and have the disease monitored with periodic CT and PET scans.

MR. CREEBY

The protocol at the time was high-dose interferon. [A type of protein produced by white blood cells, interferons have been shown to help stop the growth and spread of cancer cells.] It required infusions five days a week for a month, during which I’d have to stay home, unable to work — and then I’d have to inject myself three times a week for the next 11 months. When I learned that there was already a 50-50 chance that the melanoma would come back anyway — and that interferon would only increase the odds of it not returning by an additional 10 percent — I decided to forgo the injections and have the disease monitored with periodic CT and PET scans.

JAMES ALLISON

Dendritic cells are antigen-presenting cells [APCs]. APCs are what get the body’s immune response going. They take inside themselves infections, viruses — even dying tumor cells — and break down the antigens on the cell surfaces into smaller pieces called peptides. They then display these peptides to the body’s T cells. Receptors on the surface of the T cells recognize the peptides, bind to them, and become activated. Thousands of T cells are generated that can now go out and do their work — which is to kill target cells that express the antigen presented by the APCs. So the notion was to take advantage of these antigen-bearing dendritic cells to initiate an immune response against the melanoma.

[Antigen-presenting cells] are what get the body’s immune response going. The notion was to take advantage of these antigen-bearing dendritic cells to initiate an immune response against the melanoma.

DR. WOLCHOK

In most patients with Stage 3 melanoma there is about a 50-50 chance of melanoma coming back. Some people are at higher risk and some at lower, but generally that’s the reality.

JAMES ALLISON

Dendritic cells are antigen-presenting cells [APCs]. APCs are what get the body’s immune response going. They take inside themselves infections, viruses — even dying tumor cells — and break down the antigens on the cell surfaces into smaller pieces called peptides. They then display these peptides to the body’s T cells. Receptors on the surface of the T cells recognize the peptides, bind to them, and become activated. Thousands of T cells are generated that can now go out and do their work — which is to kill target cells that express the antigen presented by the APCs. So the notion was to take advantage of these antigen-bearing dendritic cells to initiate an immune response against the melanoma.

[Antigen-presenting cells] are what get the body’s immune response going. The notion was to take advantage of these antigen-bearing dendritic cells to initiate an immune response against the melanoma.

DR. WOLCHOK

In most patients with Stage 3 melanoma there is about a 50-50 chance of melanoma coming back. Some people are at higher risk and some at lower, but generally that’s the reality.

JAMES ALLISON

Dendritic cells are antigen-presenting cells [APCs]. APCs are what get the body’s immune response going. They take inside themselves infections, viruses — even dying tumor cells — and break down the antigens on the cell surfaces into smaller pieces called peptides. They then display these peptides to the body’s T cells. Receptors on the surface of the T cells recognize the peptides, bind to them, and become activated. Thousands of T cells are generated that can now go out and do their work — which is to kill target cells that express the antigen presented by the APCs. So the notion was to take advantage of these antigen-bearing dendritic cells to initiate an immune response against the melanoma.

[Antigen-presenting cells] are what get the body’s immune response going. The notion was to take advantage of these antigen-bearing dendritic cells to initiate an immune response against the melanoma.

DR. WOLCHOK

In most patients with Stage 3 melanoma there is about a 50-50 chance of melanoma coming back. Some people are at higher risk and some at lower, but generally that’s the reality.

JAMES ALLISON

Dendritic cells are antigen-presenting cells [APCs]. APCs are what get the body’s immune response going. They take inside themselves infections, viruses — even dying tumor cells — and break down the antigens on the cell surfaces into smaller pieces called peptides. They then display these peptides to the body’s T cells. Receptors on the surface of the T cells recognize the peptides, bind to them, and become activated. Thousands of T cells are generated that can now go out and do their work — which is to kill target cells that express the antigen presented by the APCs. So the notion was to take advantage of these antigen-bearing dendritic cells to initiate an immune response against the melanoma.

[Antigen-presenting cells] are what get the body’s immune response going. The notion was to take advantage of these antigen-bearing dendritic cells to initiate an immune response against the melanoma.

DR. WOLCHOK

In most patients with Stage 3 melanoma there is about a 50-50 chance of melanoma coming back. Some people are at higher risk and some at lower, but generally that’s the reality.

JAMES ALLISON

Dendritic cells are antigen-presenting cells [APCs]. APCs are what get the body’s immune response going. They take inside themselves infections, viruses — even dying tumor cells — and break down the antigens on the cell surfaces into smaller pieces called peptides. They then display these peptides to the body’s T cells. Receptors on the surface of the T cells recognize the peptides, bind to them, and become activated. Thousands of T cells are generated that can now go out and do their work — which is to kill target cells that express the antigen presented by the APCs. So the notion was to take advantage of these antigen-bearing dendritic cells to initiate an immune response against the melanoma.

[Antigen-presenting cells] are what get the body’s immune response going. The notion was to take advantage of these antigen-bearing dendritic cells to initiate an immune response against the melanoma.

DR. WOLCHOK

In most patients with Stage 3 melanoma there is about a 50-50 chance of melanoma coming back. Some people are at higher risk and some at lower, but generally that’s the reality.

JAMES ALLISON

Dendritic cells are antigen-presenting cells [APCs]. APCs are what get the body’s immune response going. They take inside themselves infections, viruses — even dying tumor cells — and break down the antigens on the cell surfaces into smaller pieces called peptides. They then display these peptides to the body’s T cells. Receptors on the surface of the T cells recognize the peptides, bind to them, and become activated. Thousands of T cells are generated that can now go out and do their work — which is to kill target cells that express the antigen presented by the APCs. So the notion was to take advantage of these antigen-bearing dendritic cells to initiate an immune response against the melanoma.

[Antigen-presenting cells] are what get the body’s immune response going. The notion was to take advantage of these antigen-bearing dendritic cells to initiate an immune response against the melanoma.
I thought one of the most fascinating things was the theory behind it. That you took my blood and —

I was a member of Dr. Young’s lab then — you gave us quite a lot of your blood! [Laughter] From it, we generated lots of dendritic cells. Then we loaded these cells with peptides of gp100 and tyrosinase — two differentiation antigens derived from melanoma — and injected them back into you.

I remember you also gave me antigens from a deep-sea organism.

There’s a pigment called keyhole limpet hemocyanin, made from a sea creature called a keyhole limpet, that’s been shown to enhance the immune response against tumor antigens by interacting with T cells. In other words, this pigment is very interesting to T cells that have never seen it before.

And it did seem to work. My melanoma didn’t come back for another three years. But then I went in for a PET scan and, lo and behold, it showed I had a growth on my right adrenal gland.

Mr. Creaby’s adrenal gland was surgically removed, and Dr. Wolchok put him on temozolomide (Temodar®). It was now November 2005.

Temozolomide is licensed for the treatment of certain types of brain tumors, but we use it “off-label” for melanoma. At the time there was no clinical trial that accommodated your situation, and it seemed reasonable to try to treat any micrometastatic disease with temozolomide. It’s an oral medication without many side effects, so the risk-benefit profile was favorable.

And from November 2005 until June 2006 I was okay. Then I woke up one morning and felt a lump on the right side of my neck. It turned out to be melanoma, and the tumor was removed. You put me on GM-CSF [granulocyte macrophage colony-stimulating factor].

GM-CSF is a protein of the immune system that helps regulate immune response. There’s evidence showing that it may help rev up the immune system to fight melanoma. Again, we didn’t have a trial that would’ve accommodated your circumstances, so I was drawing from the literature for any therapies I could offer.

Unfortunately, a few months later I found another tumor on my neck.

This tumor was removed in September 2006, and Mr. Creaby underwent radiation therapy to his neck. However, in December, while showering, he discovered a lump on his left oblique muscle.
The tumor was where your “love handles” are — it felt as if I’d inserted a pickle under my skin. A CT scan showed that there was also a lesion on my left pectoral muscle as well as multiple metastases in my liver and lungs. It was all over the place. There wasn’t any possibility of surgery. But I have to be immensely thankful for the fact that this recurrence made me eligible for a clinical trial of anti-CTLA-4 [now known as ipilimumab] that was closing in two weeks. I’m blessed that I made it into the trial, and I’m blessed that it’s worked.

To learn more about Dr. Allison’s development of anti-CTLA-4, see the next page.

Whatever’s going on —
— look at it —
— and go crazy! To coin a phrase . . .

[Laughter]

There’s another aspect to this that’s important to mention. Patients who are treated with ipilimumab usually exhibit a unique pattern of response. Unlike with traditional chemotherapy — where you give someone a treatment and within a fairly predictable time period you see tumors start to get smaller and hopefully go away — ipilimumab works very differently.

Because we’re not treating the tumor, we’re treating the patient.

We’re building an army of T cells — and it may take one person six weeks to muster that army while another person’s immune response may not be seen for as long as six or seven months. During that time, some patients’ tumors may grow larger, or they may even develop new tumors as older tumors regress. There are also patients who have long periods of stable disease, meaning the tumors don’t go away, yet they don’t progress.
The Development of Anti-CTLA-4 (Ipilimumab)

For more than 20 years, James Allison’s work has focused on understanding how T cells are activated and the mechanisms that regulate their response. He was chair of the immunology program at the University of California, Berkeley, when, in 1982, he and members of his laboratory discovered the receptor that T cells use to recognize antigens on the surface of antigen-presenting cells. However, recognition alone is not enough to stimulate T cell proliferation. In the late 1980s, Dr. Allison demonstrated that a protein called CD28 found on the surface of T cells was the co-stimulatory signal needed to activate a T cell response. He uses the analogy of an automobile.

“Just turning on the ignition won’t get the car to go. There needs to be a second signal, a foot on the gas pedal so to speak. No one knew what that signal was until we showed the function of CD28.” The final part of Dr. Allison’s car analogy is the immune system’s “brake,” an immune-regulating molecule known as cytotoxic T lymphocyte-associated antigen-4, or CTLA-4. “Once your T cells have successfully killed all the invaders, CTLA-4 sends an inhibitory signal that decreases T cell production. It’s what keeps the immune system from becoming hyperactivated and attacking the body’s own tissues,” he explains. “Members of my lab and I hypothesized that if we could find a way to block CTLA-4 this might enhance antitumor T cell responses. Eventually we were able to make antibodies to temporarily block CTLA-4’s signal so that T cells could do their work unrestrained. In the simplest terms, anti-CTLA-4 takes the brakes off the immune system.”
Because any self-respecting, tumor-attacking T cell is going to be in the tumor — that’s where the action is, presumably.

DR. ALLISON

As we get more tumor specimens from patients whose tumors are regressing we’ll be able to look at the specificity of the T cells within the tumors.

DR. WOLCHOK
All my tumors have now disappeared. But during those three months after I got the first dose of ipilimumab, the tumor in my pectoral muscle blossomed, the tumors in my liver grew, and the tumors in my lungs didn’t go away — although they remained stable.

You were on a randomized double-blind study evaluating the efficacy of several different dose levels of ipilimumab. Then the blind was broken, and we discovered that your first dose was a low one. Right after you had your 12-week scans we re-induced you with the high dose.

It’s working for me. I can pretty much carry on with my normal life. My biggest side effect is itching.

Patients may experience a rash and gastrointestinal problems. But they’re almost always manageable.

I’ve been fortunate. Ipilimumab doesn’t work for everybody.

Right. And that’s what we’re trying to figure out in the Immune Monitoring Core Facility — why some people have very good, durable responses and others don’t. I want to say that we deeply appreciate all our patients who are so willing to contribute blood and tissue samples, because without them we couldn’t learn.

Your blood, Jim, has been very important to our efforts. One of the first things we did was to look in your blood for antibodies that may have been produced by your immune system to targets that we know are sometimes found on melanoma. The particular target we were interested in is a protein called New York ESO-1 [NY-ESO-1]. It was discovered here at the Ludwig Institute [by Lloyd Old, a Member of SKI’s Immunology Program and Director of the New York Branch of the Ludwig Institute for Cancer Research]. We asked Jianda to look at the amount of NY-ESO-1 antibody in your blood — and this is where it got very interesting.

To read more about the Ludwig Center for Cancer Immunotherapy at MSKCC, please see page 39.

NY-ESO-1 is a member of a special class of proteins called cancer-testis, or CT antigens. CT antigens are expressed in almost half of all melanomas and in a variety of other cancers, but not in normal adult tissues, except for the germ cells of the testes and the placenta.

You see, melanoma patients can spontaneously make immune responses to NY-ESO-1. And so you might ask, “If they can make these immune responses, then why doesn’t the tumor get controlled?” Well, maybe there isn’t enough of it, or maybe all the cells don’t have it. We don’t know the answer yet.

When you got your low dose of ipilimumab, we saw a low level of NY-ESO-1. But right after Jedd gave you the high dose, your NY-ESO-1 antibodies increased tremendously. And we also saw a beautiful T cell response. Your T cells, doing their work unrestrained, recognized NY-ESO-1. So we surmise that the T cells are indeed eliminating the tumor.
It was at this same point that all your tumors regressed and you had a complete remission.

The difficult thing is that we still don’t know for certain that the specific T cells we’re measuring are the cause of the tumor going away. The tests we have for blood are useful, but may not be the most informative.

True. As we get more tumor specimens from patients whose tumors are regressing we’ll be able to look at the specificity of the T cells within the tumors.

Because any self-respecting, tumor-attacking T cell is going to be in the tumor — that’s where the action is, presumably.

So having tumor specimens is vital. One of the great advantages of working at Memorial Sloan-Kettering is that we’re at the interface of science and medicine. There are very few institutions that could carry out the kinds of studies we’ve done — very few places that can run clinical trials and then try to understand the science of the drug they’re investigating.

Also, we’re taking what we’ve learned from analyzing patient specimens in the lab back to the animal model. We’re now starting to manipulate some of the new molecules that we see are increased in patients on ipilimumab. As we identify these molecules that seem relevant in humans, we can go back and design carefully controlled mouse experiments where we’ll learn if they’re good therapeutic targets and build layer upon layer like this, over time.

It’s really a gift to be able to bring things from the lab to the clinic and back to the lab — as Jim’s just said, to complete the circle.

It’s been wonderful to be in the same room with all of you.

Well, it’s always a thrill to meet people who have benefited from our work. [Pause] I’ve met a lot of the mice. They don’t seem to care as much.

[Laughter]
The Ludwig Center at MSKCC

Memorial Sloan-Kettering is one of six distinguished United States institutions to have been named a Ludwig Center. In 2006, the institutions shared in a $120 million gift from the Virginia and D. K. Ludwig Fund for Cancer Research, plus stock in a real-estate holding company, to create the Ludwig Centers. The Ludwig Center for Cancer Immunotherapy at MSKCC focuses on harnessing the power of the immune system to monitor and treat cancer. The support of the Ludwig Fund is accelerating the pace at which researchers can move the findings of basic scientific studies into translational work, so that promising innovative therapies and diagnostic approaches can be evaluated in people with cancer. James Allison and Jedd Wolchok serve as Director and Associate Director for Clinical Research, respectively. Jianda Yuan heads the Immune Monitoring Core Facility that is part of the Ludwig Center. That facility works to develop immune monitoring tests able to determine immune responses in patients receiving novel immunotherapies.

(Above) James Allison (left) and Jedd Wolchok (middle) serve as Director and Associate Director for Clinical Research, respectively, at the Ludwig Center for Cancer Immunotherapy at MSKCC. Jianda Yuan (right) heads the Immune Monitoring Core Facility.
One of the things I try to do now is to speak to other people with cancer. What I want is to give them hope. In other words, to tell them that there is the potential for a positive outcome.

You’re actually responsible, Jim, for at least one other person joining the ipilimumab trial even though that person was quite fearful and uncertain at first. And he’s having a very good response — in fact, such a good response that he’s missing office visits left and right because he can’t take time off from work!

James Creaby receives a maintenance dose of ipilimumab every three months to periodically reinhibit CTLA-4. He continues to show no evidence of disease. To date, approximately 3,700 patients have been treated with ipilimumab, mostly for melanoma, although it is also being evaluated for the treatment of prostate, ovarian, and kidney cancers. Collaborative investigations continue at MSKCC to refine, discover, and develop new and more-effective immunotherapies against cancer.
Education & Training
Memorial Sloan-Kettering’s training programs prepare the next generation of physicians, scientists, and other healthcare professionals for leadership roles in the life sciences and medicine, especially as related to cancer. In 2008, MSKCC trained 1,609 residents and clinical fellows; 481 postdoctoral research fellows, research scholars, and research associates; 232 PhD candidates; 29 MD/PhD candidates; 72 nursing students; and 358 medical students.

Postdoctoral training takes place after young investigators have earned their PhD degrees and provides these scientists with opportunities to initiate independent research projects under the guidance of experienced mentors who provide advice and laboratory resources.

In October, Memorial Sloan-Kettering postdoctoral researchers got the chance to showcase their accomplishments at the second annual Postdoctoral Research Symposium, held in MSKCC’s Rockefeller Research Laboratories. The event enabled the postdocs to share their latest findings with MSKCC colleagues and mentors, and other members of the Tri-Institutional community (which also includes The Rockefeller University and Weill Cornell Medical College). More than 80 scientific projects were described through oral presentations and poster discussions during the daylong event, expanded from a half day last year. The committee also added a poster competition, in which a faculty panel chose the top projects. Two posters shared first prize — one presented by Christina Stallings, in the laboratory of infectious disease specialist Michael Glickman, and the other by Roy Sillitoe, in the laboratory of developmental biologist Alexandra Joyner. The symposium culminated with a keynote address by Christine Guthrie, a leading RNA researcher and professor of biochemistry at the University of California, San Francisco.

The symposium allowed postdoctoral researchers to share findings with colleagues and interact with scientists, such as (clockwise, from top right) Alan Hall, Chair of SKI’s Cell Biology Program; MSKCC President Emeritus Paul Marks; keynote speaker Christine Guthrie, from the University of California, San Francisco; and Jayanta Chaudhuri, a molecular biologist in SKI’s Immunology Program.
In late July, MSKCC welcomed the third class of the Gerstner Sloan-Kettering Graduate School of Biomedical Sciences (GSK). The 11 students matriculating in the third class came to GSK from universities across the United States — Stanford University, the University of Puerto Rico, and the University of Wisconsin — as well as from nearby schools — New York University, the University of Massachusetts, Princeton University, Cornell University, Drexel University, the University of Rochester, and Rutgers. After completing orientation week and their first laboratory rotation, the students immersed themselves in the Gerstner Sloan-Kettering core course beginning in September. The school’s second- and third-year students have completed their core-curriculum courses and are now focusing on research projects in their thesis laboratories.

To ensure continued progress in cancer research, it is vital that young people develop and maintain an interest in science and medicine. In the fall, MSKCC held its third Major Trends in Modern Cancer Research symposium, which was moderated by MSKCC President Harold Varmus. The event is designed to stimulate high school students’ interest and excitement in medical discovery and to encourage them to consider a career in science. Aimed at both students and their teachers, the seminar drew approximately 460 students from about 60 New York City-area schools. In the program, three investigators — Kathryn Anderson, Chair of the Developmental Biology Program in the Sloan-Kettering Institute; Prasad Jallepalli, a member of SKI’s Molecular Biology Program; and Kenneth Offit, Chief of the Clinical Genetics Service in Memorial Hospital — described their individual areas of research and put that research into a larger context, explaining how the understanding of certain genes or cellular or developmental processes contributes to a deeper understanding of what goes awry in the body when cancer forms. After the presentations students had the opportunity to ask the speakers about their work.

(Clockwise, from top left): Students gather around MSKCC President Harold Varmus in the Rockefeller Research Laboratories Auditorium following the Major Trends in Modern Cancer Research symposium; Developmental Biology Program Chair Kathryn Anderson speaks with a student at the symposium; geneticist Kenneth Offit speaks about the role of inherited genes in the development of cancer; a student asks a question during the lecture; molecular biologist Prasad Jallepalli shares the details of his research with a student.
Jason M. Klein joined MSKCC as its first vice president and Chief Investment Officer. Mr. Klein oversees the Center’s complex investment portfolio, which is globally diverse and includes several niche alternative investments. He will build out a new Investment Management Division to develop in-house expertise to steward the long-term investment assets of MSKCC. Previously, Mr. Klein was the Chief Investment Officer for the Museum of Modern Art and had been a vice president and principal in the private equity division of Lehman Brothers. He has also been an equity capital markets associate at Prudential Securities and a commercial credit analyst at Chemical Bank.

Kathy Lewis was named Vice President of Public Affairs. Ms. Lewis has a long history of distinguished service in the world of healthcare and advocacy and came to MSKCC after having served for three years as President and Chief Executive Officer of the Christopher and Dana Reeve Foundation. There she was engaged in philanthropy, public relations, and other aspects of the Foundation. Previously, she spent more than 20 years at the Kessler Rehabilitation Corporation, an internationally recognized physical rehabilitation services company with facilities in ten states. At Kessler she held leadership positions in marketing, community relations, and public relations and, in 2000, was appointed Executive Vice President for Corporate Strategy and Development.
Steven C. Martin joined Memorial Hospital as Chief of the General Internal Medicine Service. Dr. Martin hopes to build on the current strengths of the service — which is made up of internists who provide pre- and perioperative consultations for MSKCC’s surgical patients and hospitalists who are dedicated to enhancing the quality of care for inpatients — and add geriatricians to the faculty to strengthen the 65+ Program and bring added expertise to the care of older adults being treated here. Prior to joining MSKCC, Dr. Martin was affiliated with Jacobi Medical Center, where he served as vice Chair of the Department of Medicine and director of the internal medicine residency program.

Steven B. Solomon was appointed Chief of the Interventional Radiology Service in the Department of Radiology. Dr. Solomon, who joined MSKCC in 2005, specializes in minimally invasive treatments carried out using image guidance, including x-ray, CT, ultrasound, and MRI. He has a particular expertise in thermal ablation — a technique that uses imaging to guide a needle to a target tumor and then destroy it through the application of heat (radiofrequency ablation) or extreme cold (cryoablation). He has invented a number of technologies that make surgery easier and has expertise in robotics and other image-guided therapies.

Simon N. Powell joined MSKCC as Chair of the Department of Radiation Oncology and the incumbent of an Enid A. Haupt Chair. Dr. Powell is a leader in research into DNA repair, including the BRCA1 and BRCA2 genes, mutations in which can sharply increase breast cancer risk. He has recently developed tests to determine if a specific breast cancer has lost the DNA repair function that is controlled by these genes, which could ultimately influence treatment decisions. He also holds a joint appointment in Sloan-Kettering Institute’s Molecular Biology Program and is interested in genomic approaches to understanding the effects of radiation on tumors as well as on normal tissue.

Monica Morrow was named Chief of the Breast Service in the Department of Surgery. She came to MSKCC from Fox Chase Cancer Center, where she had served for four years as Chair of Surgical Oncology with a clinical practice dedicated to the treatment of breast cancer. She is currently studying the way treatment choices for breast cancer surgery are made — including medical decisions as well as the factors that are important to women when making treatment choices, how well they understand their choices, and the level of conflict they experience with their surgeons. Dr. Morrow is the incumbent of the Anne Burnett Windfohr Chair of Clinical Oncology.

Isabelle Rivière is director of the newly created Cell Therapy and Cell Engineering Facility, which merges the existing cell and vaccine production activities previously handled by the Adoptive Immune Cell Therapy Facility, the Immunobiology Facility, and the Gene Transfer and Somatic Engineering Cell Facility, which Dr. Rivière led as co-director since she joined MSKCC in 1998. The new laboratory provides support to MSKCC investigators who are conducting early-stage clinical trials that require biological materials for immunotherapies, vaccines, and stem-cell-based therapies. The facility is designed to meet all manufacturing standards required by the US Food and Drug Administration to ensure patient safety.

Physician-scientist Marcel R. M. van den Brink was named Head of the Division of Hematologic Oncology in the Department of Medicine. He is an expert in allogeneic (donor-provided) blood stem cell transplantation for adult cancer patients and also heads a laboratory in SKI’s Immunology Program. His research focuses on the immunology of bone marrow transplantation and the role of T cells in graft-versus-host disease, graft-versus-tumor activity, and immune reconstitution. Prior to this appointment, Dr. van den Brink had been Chief of the Adult Bone Marrow Transplant Service since 2005. He is the incumbent of the Alan N. Houghton Chair.
Endowed Chairs

An endowed chair represents one of the highest honors that MSKCC bestows on its most talented faculty. During 2008, six staff members were named to either new or established chairs.

Breast surgeon Tari A. King was named to the newly endowed Jeanne A. Petrek Junior Faculty Chair. An expert in the surgical management of breast cancer, Dr. King also has an active interest in translational research and is the principal investigator of the Breast Surgery Research Laboratory. A major focus of her research is elucidating the molecular genetics of the invasive breast cancer risk associated with lobular carcinoma in situ. The chair she holds is named in honor of Dr. Petrek, a highly regarded breast surgeon and clinical investigator whose career at MSKCC spanned more than 20 years, from 1984 until her death in 2005. It was endowed with funds from more than 500 donors, many of whom were Dr. Petrek’s patients.

Steven M. Larson, Chief of MSKCC’s Nuclear Medicine Service, is the incumbent of the newly endowed Donna and Benjamin M. Rosen Chair in Radiology. Mr. Rosen has been a member of MSKCC’s Boards of Overseers and Managers since 1985 and currently serves on the Joint Finance and Funding Committee. He and his wife are longtime supporters of the Center’s programs. Dr. Larson is a leading physician-scientist and innovator in the field of nuclear medicine whose research focuses on the experimental aspects of molecular imaging and targeted radiotherapy. He has also used advanced imaging techniques to elucidate the causes of fundamental setbacks in previously successful treatment of cancer.

Peter T. Scardino, Chair of the Department of Surgery, is the incumbent of a newly endowed David H. Koch Chair, established in recognition of a gift from Mr. Koch, a member of MSKCC’s Boards. Dr. Scardino is an internationally recognized expert in the prognosis, early detection, and treatment of prostate cancer. He and his team have developed nomograms to predict the results of treatment, imaging studies to improve staging, and new techniques that lead to better outcomes after surgery for prostate cancer. In 1999 Dr. Scardino became the inaugural Chair of the Department of Urology and in 2006 was named to his current position. He formerly held the Florence and Theodore Baumritter/Enid Ancell Chair of Urologic Oncology.

David W. Kissane was named the incumbent of the newly endowed Jimmie C. Holland Chair. Funded by a group of generous donors with a substantial lead contribution from MSKCC Board member Jack Rudin, the chair honors Dr. Holland, who founded the Psychiatry Service at MSKCC in 1977 and 20 years later became the inaugural Chair of the Department of Psychiatry and Behavioral Sciences. She continues her clinical practice at MSKCC. Dr. Kissane succeeded Dr. Holland in 2003 and is responsible for a broad program of services, research, and training in the diagnosis and treatment of psychiatric problems experienced by cancer patients. He is internationally recognized for his work characterizing demoralization of late-stage cancer patients and distinguishing between this syndrome and depression. He formerly held an Alfred P. Sloan Chair.

Stephen D. Nimer was named to an Alfred P. Sloan Chair. Dr. Nimer, who has been Chief of the Hematology Service since he joined MSKCC in 1993, is an internationally known hematologist who has utilized novel agents and stem cell transplantation to treat malignant blood cell disorders. He established the inpatient hematology service and the adult autologous peripheral blood cell transplantation program for hematologic malignancies at MSKCC. As a Member in SKi’s Molecular Pharmacology and Chemistry Program, he has helped define the molecular defects that underlie several myeloid malignancies. The chair he holds is one of four endowed in honor of the late Alfred P. Sloan, who was well known for his commitment to biomedical research.

Andrea Ventura was named to a Geoffrey Beene Junior Faculty Chair. These chairs provide funding to outstanding young researchers at a crucial early stage in their careers and are part of the Geoffrey Beene Cancer Research Center at MSKCC, an initiative funded by a gift from the estate of the late fashion designer and philanthropist Geoffrey Beene. Dr. Ventura joined the Center in September 2008 as an Assistant Member in SKi’s Cancer Biology and Genetics Program. His laboratory studies the function of microRNAs in mammalian development, seeking to understand how these small particles act on genes to promote or suppress cancer.
The following individuals received academic appointments or promotions during the past year.

### Member Level

**Appointments**
- Philip A. Bialer
  Department of Psychiatry and Behavioral Sciences
- Paul A. Glare
  Chief, Pain and Palliative Care Service, Department of Medicine
- Meera Rathika Hameed
  Department of Pathology
- Steven C. Martin
  Chief, General Internal Medicine Service, Department of Medicine
- Monica Morrow
  Chief, Breast Service, Department of Surgery
- John P. Mulhall
  Department of Surgery
- Raul O. Parra
  Department of Surgery
- Simon N. Powell
  Chair, Department of Radiation Oncology
- Alexander Rudensky
  Immunology Program
- Gerald A. Soff
  Department of Clinical Laboratories; Department of Medicine

**Promotions**
- Ariadne M. Bach
  Department of Radiology
- Mary K. Baylies
  Developmental Biology Program
- Mark J. Bluth
  Department of Radiology
- Mercedes Castiel
  Department of Surgery
- Guido Dalbagni
  Department of Surgery
- William R. Jarnagin
  Chief, Hepatopancreatobiliary Service, Department of Surgery
- Nancy E. Mills
  Department of Medicine
- Andrew J. Roth
  Department of Psychiatry and Behavioral Sciences
- Karen D. Schupak
  Department of Radiation Oncology
- Samuel Singer
  Department of Surgery
- Satish K. Tickoo
  Department of Pathology
- Marcel R. M. van den Brink
  Head, Division of Hematologic Oncology, Department of Medicine
- Carolyn Wasserheit
  Department of Medicine
- Pat B. Zanzonico
  Department of Medical Physics; Department of Radiology

### Associate Member Level

**Appointments**
- Deborah M. Capko
  Department of Surgery
- Maxine S. Jochelson
  Department of Radiology
- Vincent F. LaRussa
  Department of Clinical Laboratories
- Vincent Laudone
  Department of Surgery
- Jason S. Lewis
  Chief, Radiochemistry Service, Department of Radiology
- Barbara Waiejbro-Kandel
  Department of Radiology
- Jacqueline F. Bromberg
  Department of Medicine
- Carol L. Brown
  Department of Surgery
- Chih-Shan Jason Chen
  Department of Medicine
- Anne M. Covey
  Department of Radiology
- Michael D’Angelica
  Department of Surgery
- Gary E. Deng
  Department of Medicine
- Raja M. Flores
  Department of Surgery
- Venera Grasso
  Department of Medicine
- Prasad V. Jallepalli
  Molecular Biology Program
- Noah D. Kauff
  Department of Medicine; Department of Surgery
- Delia Keating
  Department of Radiology
- Kim Kramer
  Department of Pediatrics
- Vivek T. Malhotra
  Department of Anesthesiology and Critical Care Medicine
- James G. Mechalakos
  Department of Medical Physics
- Babak J. Mehrara
  Department of Surgery
- Sadek Nehme
  Department of Radiology; Department of Medical Physics
- Kenneth K. Ng
  Department of Medicine
- Ariela Noy
  Department of Medicine
- Snehal Patel
  Department of Surgery
- Viviane S. Tabar
  Department of Neurosurgery
- Derek S. Tan
  Molecular Pharmacology and Chemistry Program
- Larissa K. F. Temple
  Department of Surgery
- Tanya M. Trippett
  Department of Pediatrics
- Yukio Sonoda
  Department of Surgery
- Jedd D. Wolchok
  Department of Medicine
- Richard J. Wong
  Department of Surgery
<table>
<thead>
<tr>
<th>PATIENT CARE</th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Admissions: Adults</td>
<td>18,584</td>
<td>19,624</td>
<td>19,626</td>
<td>20,195</td>
<td>21,039</td>
</tr>
<tr>
<td>Patient Admissions: Children</td>
<td>1,480</td>
<td>1,532</td>
<td>1,553</td>
<td>1,673</td>
<td>1,650</td>
</tr>
<tr>
<td>Total Admissions</td>
<td>20,064</td>
<td>21,156</td>
<td>21,179</td>
<td>21,868</td>
<td>22,689</td>
</tr>
<tr>
<td>Total Patient Days</td>
<td>135,762</td>
<td>139,301</td>
<td>136,920</td>
<td>137,787</td>
<td>139,847</td>
</tr>
<tr>
<td>Average Patient Stay (days)</td>
<td>6.8</td>
<td>6.6</td>
<td>6.5</td>
<td>6.3</td>
<td>6.2</td>
</tr>
<tr>
<td>Bed Occupancy Rate(1)</td>
<td>87.3%</td>
<td>88.3%</td>
<td>88.1%</td>
<td>87.4%</td>
<td>88%</td>
</tr>
<tr>
<td>Outpatient MD Visits: Manhattan</td>
<td>340,179</td>
<td>351,452</td>
<td>363,458</td>
<td>368,200</td>
<td>384,889</td>
</tr>
<tr>
<td>Outpatient MD Visits: Regional Network</td>
<td>60,789</td>
<td>70,170</td>
<td>67,702</td>
<td>75,631</td>
<td>81,995</td>
</tr>
<tr>
<td>Total Outpatient MD Visits</td>
<td>400,968</td>
<td>421,622</td>
<td>431,160</td>
<td>443,831</td>
<td>466,884</td>
</tr>
<tr>
<td>Screening Visits</td>
<td>29,425</td>
<td>31,383</td>
<td>31,198</td>
<td>30,200</td>
<td>28,888</td>
</tr>
<tr>
<td>Surgical Cases</td>
<td>15,431</td>
<td>16,043</td>
<td>16,329</td>
<td>16,951</td>
<td>16,035</td>
</tr>
<tr>
<td>Radiation Treatments and Implants: Manhattan</td>
<td>63,240</td>
<td>62,754</td>
<td>59,369</td>
<td>57,307</td>
<td>58,494</td>
</tr>
<tr>
<td>Radiation Treatments and Implants: Regional Network</td>
<td>45,980</td>
<td>47,751</td>
<td>44,175</td>
<td>44,615</td>
<td>43,550</td>
</tr>
<tr>
<td>Total Radiation Treatments and Implants</td>
<td>109,220</td>
<td>110,505</td>
<td>103,544</td>
<td>101,922</td>
<td>102,044</td>
</tr>
<tr>
<td>X-ray Examinations and Special Procedures</td>
<td>274,124</td>
<td>291,127</td>
<td>305,404</td>
<td>329,329</td>
<td>346,157</td>
</tr>
<tr>
<td>Clinical Investigation Protocols (2)</td>
<td>436</td>
<td>445</td>
<td>460</td>
<td>493</td>
<td>522</td>
</tr>
</tbody>
</table>

(1) Based on adjusted bed count
(2) Excludes studies closed to accrual
### STAFF

<table>
<thead>
<tr>
<th></th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Center&lt;sup&gt;(1)(2)&lt;/sup&gt;</td>
<td>692</td>
<td>726</td>
<td>798</td>
<td>766</td>
<td>826</td>
</tr>
<tr>
<td>Hospital Attending Staff</td>
<td>620</td>
<td>650</td>
<td>713</td>
<td>672</td>
<td>727</td>
</tr>
<tr>
<td>Sloan-Kettering Institute Members&lt;sup&gt;(3)&lt;/sup&gt;</td>
<td>111</td>
<td>116</td>
<td>122</td>
<td>128</td>
<td>133</td>
</tr>
<tr>
<td>Registered Nurses</td>
<td>1,262</td>
<td>1,377</td>
<td>1,504</td>
<td>1,615</td>
<td>1,738</td>
</tr>
<tr>
<td>Total Employees&lt;sup&gt;(1)&lt;/sup&gt;</td>
<td>8,320</td>
<td>8,760</td>
<td>9,309</td>
<td>9,917</td>
<td>10,509</td>
</tr>
<tr>
<td>Volunteers</td>
<td>903</td>
<td>877</td>
<td>895</td>
<td>848</td>
<td>871</td>
</tr>
</tbody>
</table>

<sup>(1)</sup> All Hospital Attending and Institute Members hold appointments in the Center; in 2008, 34 staff members held appointments in both the Institute and the Hospital

<sup>(2)</sup> Includes professional support staff appointments

<sup>(3)</sup> Includes all clinicians, scientists, nurses, other health professionals, and support staff

### EDUCATION

<table>
<thead>
<tr>
<th></th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Residents and Clinical Fellows — Positions</td>
<td>377</td>
<td>385</td>
<td>412</td>
<td>419</td>
<td>414</td>
</tr>
<tr>
<td>Residents and Clinical Fellows — Annual Total</td>
<td>1,311</td>
<td>1,347</td>
<td>1,421</td>
<td>1,687</td>
<td>1,609</td>
</tr>
<tr>
<td>Research Fellows</td>
<td>336</td>
<td>340</td>
<td>400</td>
<td>404</td>
<td>254</td>
</tr>
<tr>
<td>Research Scholars</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>140</td>
</tr>
<tr>
<td>Research Associates</td>
<td>63</td>
<td>65</td>
<td>62</td>
<td>63</td>
<td>87</td>
</tr>
<tr>
<td>Senior Research Scientists</td>
<td>28</td>
<td>30</td>
<td>34</td>
<td>40</td>
<td>46</td>
</tr>
<tr>
<td>Frank A. Howard Scholars</td>
<td>—</td>
<td>—</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>PhD Candidates</td>
<td>147</td>
<td>155</td>
<td>163</td>
<td>195</td>
<td>232</td>
</tr>
<tr>
<td>MD/PhD Candidates</td>
<td>28</td>
<td>25</td>
<td>23</td>
<td>24</td>
<td>29</td>
</tr>
<tr>
<td>Registrants in Continuing Medical Education Programs</td>
<td>1,863</td>
<td>2,010</td>
<td>2,140</td>
<td>2,035</td>
<td>2,115</td>
</tr>
<tr>
<td>Medical Observers</td>
<td>455</td>
<td>488</td>
<td>534</td>
<td>522</td>
<td>561</td>
</tr>
<tr>
<td>Medical Students</td>
<td>302</td>
<td>318</td>
<td>332</td>
<td>368</td>
<td>358</td>
</tr>
<tr>
<td>Nursing Students</td>
<td>84</td>
<td>62</td>
<td>71</td>
<td>61</td>
<td>72</td>
</tr>
<tr>
<td>Social Work Students</td>
<td>6</td>
<td>5</td>
<td>6</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Radiation Oncology Technology Students</td>
<td>20</td>
<td>17</td>
<td>16</td>
<td>16</td>
<td>15</td>
</tr>
<tr>
<td>Cytotechnology Students</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Physical Therapy Students</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Occupational Therapy Students</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>5</td>
</tr>
</tbody>
</table>
### Financial Summary

#### Revenues and Expenses (in Thousands)

<table>
<thead>
<tr>
<th></th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Operating Revenues</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient Care Revenue</td>
<td>$1,094,797</td>
<td>$1,249,379</td>
<td>$1,398,393</td>
<td>$1,531,639</td>
<td>$1,606,989</td>
</tr>
<tr>
<td>Grants and Contracts</td>
<td>119,396</td>
<td>117,428</td>
<td>129,693</td>
<td>149,275</td>
<td>163,352</td>
</tr>
<tr>
<td>Contributions Allocated to Operations</td>
<td>69,114</td>
<td>74,277</td>
<td>83,538</td>
<td>95,481</td>
<td>108,844</td>
</tr>
<tr>
<td>Royalty Income</td>
<td>61,128</td>
<td>46,297</td>
<td>44,558</td>
<td>38,302</td>
<td>94,131</td>
</tr>
<tr>
<td>Other Income</td>
<td>64,780</td>
<td>34,294</td>
<td>39,439</td>
<td>39,902</td>
<td>41,963</td>
</tr>
<tr>
<td>Investment Return Allocated to Operations</td>
<td>70,635</td>
<td>88,664</td>
<td>116,143</td>
<td>113,131</td>
<td>116,546</td>
</tr>
<tr>
<td><strong>Total Operating Revenues</strong></td>
<td>1,490,449</td>
<td>1,627,502</td>
<td>1,837,847</td>
<td>1,997,170</td>
<td>2,164,947</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Operating Expenses</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compensation and Fringe Benefits</td>
<td>813,584</td>
<td>880,565</td>
<td>966,034</td>
<td>1,061,946</td>
<td>1,164,155</td>
</tr>
<tr>
<td>Purchased Supplies and Services</td>
<td>464,147</td>
<td>525,120</td>
<td>594,671</td>
<td>659,488</td>
<td>684,872</td>
</tr>
<tr>
<td>Provision for Bad Debts and Assessments</td>
<td>34,274</td>
<td>40,506</td>
<td>41,978</td>
<td>13,387</td>
<td>6,823</td>
</tr>
<tr>
<td>Depreciation and Amortization</td>
<td>130,974</td>
<td>135,143</td>
<td>139,402</td>
<td>157,494</td>
<td>175,870</td>
</tr>
<tr>
<td>Interest Expense</td>
<td>20,808</td>
<td>24,205</td>
<td>45,463</td>
<td>54,872</td>
<td>59,023</td>
</tr>
<tr>
<td>Less Fund Raising Expenses Transferred to Non-Operating Income (Expenses)</td>
<td>(25,697)</td>
<td>(29,631)</td>
<td>(28,390)</td>
<td>(33,523)</td>
<td>(36,048)</td>
</tr>
<tr>
<td><strong>Total Operating Expenses</strong></td>
<td>1,438,090</td>
<td>1,575,908</td>
<td>1,759,158</td>
<td>1,913,664</td>
<td>2,054,695</td>
</tr>
<tr>
<td><strong>Income from Operations</strong></td>
<td>$ 52,359</td>
<td>$ 51,594</td>
<td>$ 78,689</td>
<td>$ 83,506</td>
<td>$ 110,252</td>
</tr>
</tbody>
</table>

#### Philanthropy (in Thousands)

<table>
<thead>
<tr>
<th></th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>$ 152,461</td>
<td>$ 162,335</td>
<td>$ 193,538</td>
<td>$ 172,604</td>
<td>$ 246,335</td>
</tr>
<tr>
<td>Temporarily Restricted</td>
<td>42,256</td>
<td>26,157</td>
<td>61,453</td>
<td>(12,419)</td>
<td>30,990</td>
</tr>
<tr>
<td>Permanently Restricted</td>
<td>11,811</td>
<td>10,191</td>
<td>43,737</td>
<td>78,835</td>
<td>1,778</td>
</tr>
<tr>
<td><strong>Total Philanthropy</strong></td>
<td>$ 206,528</td>
<td>$ 198,683</td>
<td>$ 298,728</td>
<td>$ 239,020</td>
<td>$ 279,103</td>
</tr>
</tbody>
</table>

#### Capital Spending (in Thousands)

<table>
<thead>
<tr>
<th></th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capital Spending</td>
<td>$ 272,218</td>
<td>$ 297,519</td>
<td>$ 309,524</td>
<td>$ 273,944</td>
<td>$ 345,135</td>
</tr>
</tbody>
</table>

Memorial Sloan-Kettering’s financial statements are available by writing to the Department of Public Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 or the New York State Department of Law, Office of the Attorney General, Charities Bureau, 120 Broadway, New York, NY 10271-0332
Boards of Overseers and Managers
Memorial Sloan-Kettering Cancer Center

James D. Robinson III
Honorary Chairman

Douglas A. Warner III
Chairman

Richard I. Beattie
Vice Chairman of Boards, Chairman, Board of Managers, Memorial Sloan-Kettering Cancer Center

Louis V. Gerstner, Jr.
Vice Chairman of Boards, Chairman, Board of Managers, Sloan-Kettering Institute

Harold Varmus, MD
President and Chief Executive Officer, Memorial Sloan-Kettering Cancer Center

Clifton S. Robbins
Treasurer

Peter O. Crisp
Secretary

Paul A. Marks, MD
President Emeritus

Frederick R. Adler
Richard I. Beattie
Mrs. Edwin M. Burke
Mrs. John J. Byrne
Mrs. Joseph A. Califano, Jr.
Peter O. Crisp
Stanley F. Druckenmiller
Anthony B. Evnin
Steve Forbes
Richard N. Foster
Stephen Friedman
Ellen V. Futter
Philip H. Geier, Jr.
Louis V. Gerstner, Jr.
Jonathan N. Graye
John R. Gunn
Mrs. Charles Gwathmey
William B. Harrison, Jr.
Benjamin W. Heineman, Jr.

Mrs. Peter D. Jones
Mrs. Ann Dibble Jordan
David H. Koch
Marie-Josée Kravis
Evelyn H. Lauder
Mrs. Jean Remmel Little
Mrs. John L. Marion
Paul A. Marks, MD
Donald B. Marron
James G. Niven
Hutham S. Olayan
E. Stanley O’Neal
Bruce C. Ratner
Clifton S. Robbins
Josephine Robertson
James D. Robinson III
Benjamin M. Rosen
David M. Rubenstein
Jack Rudin

Lewis A. Sanders
Fayez S. Sarofim
Norman C. Selby
Stephen C. Sherrill
Peter J. Solomon
William C. Steere, Jr.
J. McClain Stewart
Scott M. Stuart
Carl W. Timpson, Jr.
Harold Varmus, MD
Lucy R. Waletzky, MD
Douglas A. Warner III
Sanford I. Weill
Jon Winkelried
Deborah C. Wright
Jeff Zucker
Mortimer B. Zuckerman

Board of Overseers Emeriti

Mrs. Elmer H. Bobst
Richard M. Furlaud
James W. Kinnear
Elizabeth J. McCormack, PhD
Mrs. Arnold Schwartz
H. Virgil Sherrill

Board of Scientific Consultants

Richard Axel, MD
Philip A. Cole, MD, PhD
Nancy E. Davidson, MD
Titia de Lange, PhD
James R. Downing, MD
Laurie Glimcher, MD
Joseph L. Goldstein, MD
Gregory Hannon, PhD
Tyler Jacks, PhD
Caryn Lerman, PhD
Arthur D. Levinson, PhD
Frank McCormick, PhD
Paul Nurse, PhD, FRS
Stanley R. Riddell, MD
Janet Rossant, PhD, FRS
William R. Sellers, MD
Gregory L. Verdine, PhD
Ralph Weissleder, MD, PhD
Irving L. Weissman, MD
MEDICAL BOARD

CHAIR
Robert E. Wittes, MD
Vincent Astor Chair of Clinical Research

David R. Artz, MD
Gay Bailey, RN

Richard J. Beattie, JD
Colin B. Begg, PhD
Ellin Berman, MD
George J. Bosl, MD
Kevin Browne, RN
Michelle Burke, RN
Lisa M. DeAngelis, MD
Mary Dowling, RN
Roderick J. Francis, MD
Jeffrey S. Groeger, MD
John R. Gunn
Philip H. Gutin, MD
William J. Hoskins, MD
Hedvig Hricak, MD, PhD
William R. Jarnagin, MD
Lewis J. Kampel, MD
Thomas J. Kelly, MD, PhD
Aileen Killen, PhD, RN
David W. Kissane, MD
Robert C. Kurtz, MD
Michael P. La Quaglia, MD
Charles D. Lucarelli, RPh
Kathryn Martin
Mary Jane Massie, MD
Mary McCabe, RN
Elizabeth Nelkin McCormick, MSn, RN
Larry Norton, MD
Eileen M. O’Reilly, MBCh, BAO
Richard J. O’Reilly, MD
David G. Pistler, MD
Simon N. Powell, MD, PhD
Marc K. Rosenblum, MD
Jean M. St. Germain, MS
Leonard B. Saltz, MD
Peter T. Scardino, MD
Harold Varmus, MD
Roger S. Wilson, MD

DEPARTMENT OF ANESTHESIOLOGY AND CRITICAL CARE MEDICINE

CHAIR AND ATTENDING
Roger S. Wilson, MD
Founder’s Chair

ATTENDINGS
David Amar, MD
Ruth A. Borchardt, MD
Dawn P. Desiderio, MD
Mary Ellen Fischer, MD
Florence J. Grant, MD
Jeffrey S. Groeger, MD
Neil A. Halpern, MD
Paul M. Heerdt, MD, PhD
Anne C. Kolker, MD
Ronald A. Kross, MD
William L. Marx, MD
Stephen M. Pastores, MD
Diane E. Stover, MD
Alisa C. Thorne, MD
Robert A. Veselis, MD
Lisa R. Barr, MD
Paul H. Dalecki, MD
Jamie A. Fortunoff, MD
Alan L. Kotin, MD
Vivek T. Malhotra, MD
Roger E. Padilla, MD
Josephine P. Ragasa, MD
Clara Broad, MD
Mohit Chawla, MD
Sanjay Chawla, MD
Kenneth H. Cubert, MD
Anahita Dabo, MD
Oscar E. Del Valle, MD
Marc B. Feinstein, MD
Rodney H. Garcia, MD
Amitabh Gulati, MD

ASSISTANT ATTENDINGS
Eric R. Kelhoffer, MD
Jennifer Massiceti, PhD
Eileen P. McAleer, MD
Leslie S. Ojea, MD
Alessia C. Pedoto, MD
Kane O. Pryor, MBBS
Nina D. Raof, MD
Ruth A. Reinsel, PhD
Luis E. Tollefson, MD
Louis P. Voigt, MD
InSTRUCTORS
Arny Lu, MD, MPH
Elizabeth Fay Rieh, MD
Cindy Beng-Imm Yeo, MD

DEPARTMENT OF CLINICAL LABORATORIES

CHAIR AND ATTENDING
Martin Fleisher, PhD

ATTENDINGS
Ann M. Dnistrian, PhD
Bo DuPont, MD, DSc
Timothy E. Eieh, MD
Hans G. Lilja, MD, PhD
Peter G. Maslak, MD
Eric Pamer, MD
Enid A. Haupt Chair in Clinical Investigation
Lilian M. Reich, MD
Gerald A. Soff, MD
David L. Wuest, MD
Vincent F. Larussa, PhD
Celia J. Menendez-Botet, PhD
Trudy Nan Smal, MD

ASSOCIATE ATTENDINGS
Reiner J. Brentjens, MD, PhD
Alex J. Rai, PhD
Larry J. Smith, PhD

DEPARTMENT OF EPIDEMIOLOGY AND BIOSTATISTICS

CHAIR AND ATTENDING
Colin B. Begg, PhD
Eugene W. Kettering Chair

ATTENDINGS
Glenn Heller, PhD
Chris Sander, PhD
Peter B. Bach, MD
Jonine L. Bernstein, PhD
Mithat Gonen, PhD
Adam B. Olshen, PhD
Katherine Panagopoulos, DrPH
Malcolm C. Pike, PhD
Jaya M. Satagopan, PhD
Howard T. Thaler, PhD
Andrew J. Vickers, DPhil
Ann G. Zauber, PhD
Vuelin Li, PhD
Chaya S. Moskowitz, PhD
Susan A. Oliveria, ScD, MPH
Sara H. Olson, PhD
Irene Orlow, PhD
Irina Ostrovynaya, PhD
Sujata Patil, PhD
Li-Xuan Qin, PhD
Talya Salz, PhD
Ronglai Shen, PhD
Zhigang Zhang, PhD

ASSOCIATE ATTENDINGS
Ethan M. Basch, MD
Victoria S. Blinder, MD
Marinella Capanu, PhD
Elena B. Elkin, PhD
Lawrence S. Engel, PhD
Mia M. Gaudet, PhD
Alexia E. Iasonos, PhD
Yue-lin Li, PhD
Chaya S. Moskowitz, PhD
Susan A. Oliveria, ScD, MPH
Sara H. Olson, PhD
Irene Orlow, PhD
Irina Ostrovynaya, PhD
Sujata Patil, PhD
Li-Xuan Qin, PhD
Talya Salz, PhD
Ronglai Shen, PhD
Zhigang Zhang, PhD
### DEPARTMENT OF NEUROLOGY

**Chair and Attending**
Lisa M. DeAngelis, MD  
Lillian Rothman Berkman Chair in Honor of Jerome B. Posner

<table>
<thead>
<tr>
<th>ATTENDINGS</th>
<th>NEUROLOGY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ronald G. Blasberg, MD</td>
<td>Neal Rosen, MD, PhD</td>
</tr>
<tr>
<td>Robert B. Darnell, MD, PhD</td>
<td>Enid A. Haupt Chair in Medical Oncology</td>
</tr>
<tr>
<td>Kathleen M. Foley, MD</td>
<td>Jonathan D. Victor, MD, PhD</td>
</tr>
<tr>
<td><em>The Society of Memorial Sloan-Kettering Cancer Center Chair</em></td>
<td><em>Associate Attending</em></td>
</tr>
<tr>
<td>Paul A. Glare, MBBS</td>
<td>Lauren E. Abrey, MD</td>
</tr>
<tr>
<td>Eric C. Holland, MD, PhD</td>
<td>Ying-Xian Pan, PhD</td>
</tr>
<tr>
<td><em>Emily Tow Jackson Chair in Oncology</em></td>
<td><em>Assistant Attending</em></td>
</tr>
<tr>
<td>Eugenie A. M. T. Obbens, MD, PhD</td>
<td>Edward K. Avila, DO</td>
</tr>
<tr>
<td>Gavril W. Pasternak, MD, PhD</td>
<td>Xi Chen, MD, PhD</td>
</tr>
<tr>
<td>Anne Burnett Tandy Chair of Neurology</td>
<td>Alexie Cintron, MD</td>
</tr>
<tr>
<td>Jerome B. Posner, MD</td>
<td>Denise D. Correa, PhD</td>
</tr>
<tr>
<td>American Cancer Society Clinical Research Professor</td>
<td>Christian M. Custodio, MD</td>
</tr>
<tr>
<td>George C. Cotzias Chair of Neura-Oncology</td>
<td>Igor T. Gavrilovic, MD</td>
</tr>
<tr>
<td></td>
<td>Yvona Griffio, MD</td>
</tr>
</tbody>
</table>

**Associate Attending**

- Adilia M. V. Hornigo, MD, PhD  
- Yasmin Khakoo, MD  
- Erik J. Kobylarz, MD, PhD  
- Andrew B. Lassman, MD  
- Paolo L. Manfredi, MD  
- Ingo K. Mellinghoff, MD  
- Natalie Moryl, MD  
- Craig P. Nolan, MD  
- Antonio M. P. Omori, MD  
- Sonia K. Sandhu, DO  
- Jonas M. Sokolof, DO  
- Michael D. Stubblefield, MD  
- Roma Tickoo, MD, MPH  

**Instructor**

- Timothy R. Gershon, MD, PhD

### DEPARTMENT OF NEUROSURGERY

**Chair and Attending**
Philip H. Gutin, MD  
Fred Lebow Chair in Neuro-Oncology

<table>
<thead>
<tr>
<th>ATTENDINGS</th>
<th>NEURO-ONCOLOGY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric C. Holland, MD, PhD</td>
<td>Neal Rosen, MD, PhD</td>
</tr>
<tr>
<td><em>Emily Tow Jackson Chair in Oncology</em></td>
<td><em>Enid A. Haupt Chair in Medical Oncology</em></td>
</tr>
<tr>
<td>Samuel H. Selesnick, MD</td>
<td>Jonathan D. Victor, MD, PhD</td>
</tr>
<tr>
<td>Philip E. Stieg, MD</td>
<td><em>Associate Attending</em></td>
</tr>
</tbody>
</table>

**Associate Attending**

- Mark H. Bilsky, MD  
- Michael Kaplitt, MD, PhD  
- Mark M. Souweidane, MD  
- Lorenz P. Studer, MD  
- Viviane S. Tabar, MD

**Assistant Attending**

- Cameron W. Brennan, MD  
- Sonia K. Sandhu, DO

### DEPARTMENT OF PATHOLOGY

**Chair and Attending**
Marc K. Rosenblum, MD  
James Ewing Alumni Chair of Pathology

<table>
<thead>
<tr>
<th>PATHOLOGY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Klaus J. Busam, MD</td>
</tr>
<tr>
<td>Daniel A. Filippa, MD</td>
</tr>
<tr>
<td>Meera Rathika Hameed, MBBS</td>
</tr>
<tr>
<td>Suresh C. Jhanwar, PhD</td>
</tr>
<tr>
<td>David S. Klimstra, MD</td>
</tr>
<tr>
<td>Marc Ladanyi, MD</td>
</tr>
<tr>
<td>Victor E. Reuter, MD</td>
</tr>
<tr>
<td>Robert A. Soslow, MD</td>
</tr>
<tr>
<td>Satish K. Tickoo, MD</td>
</tr>
<tr>
<td>William D. Travis, MD</td>
</tr>
<tr>
<td>Maureen F. Zakowski, MD</td>
</tr>
<tr>
<td><em>Associate Attending</em></td>
</tr>
<tr>
<td>Cristina Antonescu, MD</td>
</tr>
<tr>
<td>Edi Brogi, MD, PhD</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

**Instructors**

- Nora Katabi, MD  
- André L. Moreira, MD, PhD  
- Melissa P. Murray, DO  
- Kay J. Park, MD  
- Melissa P. Pullitzer, MD  
- Alex J. Rai, PhD  
- Natasha Rekhtman, MD, PhD  
- Laura H. Tang, MD, PhD  
- Efsevia Vakiani, MD, PhD  
- Liying Zhang, MD, PhD

**Instructor**

- Karuna Garg, MBBS  
- Jason T. Huse, MD, PhD  
- Christine Ann Wynveen, MD
DEPARTMENT OF PEDIATRICS

CHAIR AND ATTENDING
Richard J. O'Reilly, MD
Claire L. Tow Chair in Pediatric Oncology Research

ATTENDINGS
David H. Abramson, MD
Nai-Kong V. Cheung, MD, PhD
Enid A. Haupt Chair in Pediatric Oncology
Rubin S. Cooper, MD
Donna DiMichelle, MD
Patricia A. Giardina, MD
Nancy A. Kernan, MD
Brian H. Kushner, MD
Michael P. La Quaglia, MD
Paul A. Meyers, MD
Kevin C. Oeffinger, MD, PhD
Stephen and Barbara Friedman Chair
Charles A. Sklar, MD
Laurel J. Steinherz, MD
Peter G. Steinherz, MD

ASSOCIATE ATTENDINGS
Farid Boulad, MD
James B. Bussel, MD
Ira J. Dunkel, MD
Bruce M. Greenwald, MD
Kim Kramer, MD
Trudy Nan Small, MD
Tanya M. Trippett, MD
Maria G. Vogiatzi, MD
Leonard H. Wexler, MD

ASSISTANT ATTENDINGS
Abraham S. Bartell, MD
Naomi B. Bishop, MD
Sheila J. Carroll, MD
Alejandro Diaz, MD
Jennifer S. Ford, PhD
Joy D. Howell, MD
Deyin Doreen Hsing, MD
Rosandra N. Kaplan, MD
Yasmin Khakoo, MD

Martha C. Kutko, MD
David C. Lyden, MD, PhD
Shakeel Modak, MBBS
Roya Motaghedi, MD
Steven Pon, MD
Susan E. Prockop, MD
Richard A. Rosencrantz, MD
Peter M. C. Savard, MD
Chani Traube, MD

INSTRUCTORS
Oren Josh Becher, MD
Alexander Ja-Ho Chou, MD
Timothy R. Gershon, MD, PhD
Stephen W. Gilheeney, MD
Julia A. Kearney, MD
Rachel Kobos, MD
Pamela Merola, MD
Christine Anne Prattilis, MD
Neerav Shukla, MD

DEPARTMENT OF PSYCHIATRY AND BEHAVIORAL SCIENCES

CHAIR AND ATTENDING
David W. Kissane, MBBS
Jinnie C. Holland Chair

ATTENDINGS
Timothy A. Ahles, PhD
Philip A. Bialer, MD
William S. Breitbart, MD
Jimmie C. Holland, MD
Wayne E. Chapman Chair of Psychiatric Oncology
Marguerite S. Lederberg, MD
Mary Jane Massie, MD
Andrew J. Roth, MD

ASSOCIATE ATTENDINGS
Katherine N. DuHamel, PhD
Jamie S. Ostroff, PhD
Steven D. Passik, PhD

ASSISTANT ATTENDINGS
Abraham S. Bartell, MD
Richard Brown, PhD
Jack E. Burkhalter, PhD
Carma L. Bylund, PhD
Jeanne Carter, PhD
Jennifer S. Ford, PhD
Miriam M. Friedlander, MD

Jennifer L. Hay, PhD
Karen E. Hurley, PhD
Tomer T. Levin, MBBS
Yuelin Li, PhD
Christian J. Nelson, PhD
Shannon R. Poppito, PhD
Ruth A. Reinsel, PhD
Elizabeth L. Ryan, PhD

INSTRUCTORS
Julia A. Kearney, MD
Talia I. Zaider, PhD

DEPARTMENT OF RADIATION ONCOLOGY

CHAIR AND ATTENDING
Simon N. Powell, MBBS, PhD
Enid A. Haupt Chair in Radiation Oncology

ATTENDINGS
David H. Abramson, MD
Adriana Haimovitz-Friedman, PhD
Gloria C. Li, PhD
Beryl McCormick, MD
Karen D. Schupak, MD
Joachim Yahlom, MD
Michael J. Zelefsky, MD

ASSOCIATE ATTENDINGS
Kaled M. Atekwana, MD
Daphna Y. Gelblum, MD
Nancy Lee, MD
Borys R. Mychalczak, MD
Kenneth E. Rosenzweig, MD
Suzanne L. Wolden, MD

ASSISTANT ATTENDINGS
Kathryn F. Patton Beal, MD
Karen Borofsky, MD
Timothy A. Chan, MD, PhD

Brett Wayne Cox, MD
Richard M. Gewanter, MD
Karyn A. Goodman, MD
Alice Yoosun Ho, MD
Marisa A. Kollmeier, MD
James E. Lee, MD
Boris Mueller, MD
Melissa R. Remis, MD
Helen L. Sidebotham, MD
Yoshiya Yamada, MD
DEPARTMENT OF RADIOLOGY

CHAIR AND ATTENDING
Hedvig Hricak, MD, PhD
Carroll and Milton Petrie Chair

ATTENDINGS
Andrea F. Abramson, MD
Sara J. Abramson, MD
Ariadne M. Bach, MD
Ronald G. Blasberg, MD
Mark J. Bluth, MD
Karen T. Brown, MD
James F. Caravelli, MD
Jorge A. Carrasquillo, MD
D. David Dershaw, MD
Yuman Fong, MD
Murray F. Brennan Chair in Surgery
George I. Getrajdman, MD
Lucy E. Hann, MD
Robert T. Heelan, MD
Andrei I. Holodny, MD
John L. Humm, PhD
Peter Kijewski, PhD
Jason A. Koutcher, MD, PhD
George Krol, MD
Steven M. Larson, MD
Donna and Benjamin M. Rosen Chair in Radiology

ASSOCIATE ATTENDINGS
Linda R. Aboody, MD
Timothy J. Akhurst, MD
Douglas J. Ballon, PhD
Michael S. Baum, MD
Lynn A. Brody, MD
Anne M. Covey, MD
Otilia-Liana Dumitrescu, MD
Arthur A. Fruauff, MD
Michelle S. Ginsberg, MD
Marc J. Gollub, MD
Linda A. Heier, MD
Tunç A. Iryiboz, MD
Stefanie S. Jacobs, MD
Maxine S. Jochelson, MD
Karen B. Karlson, MD
Delia M. Keating, MD
Jason S. Lewis, PhD
Eric Lis, MD
Elizabeth A. Morris, MD
Sadek Nehmeh, PhD
Heiko Schöder, MD
Marc Z. Simmons, MD
Amy Singer, MD
Peter M. Smith-Jones, PhD
Constantinos T. Sofocleous, MD, PhD
Stephen B. Solomon, MD
Hilda E. Stambuk, MD
Jean M. Torrisi, MD
Barbara Wajsbrot-Kandel, MD
Corinne B. Winston, MD
Kristen L. Zakian, PhD
Binheng Zhao, PhD

ASSISTANT ATTENDINGS
Oguz Akin, MD
William Alago, Jr., MD
Michelle S. Bradbury, MD, PhD
Sandra Brennan, MB, BCh, BAO
Betty A. Caravella, MD
Joshua Chair, DO
Donna D. D’Alessio, MD
Amita Dave, PhD
Mark Phillip S. Dunphy, DO
Kimberly N. Feigin, MD
Stephen E. Fleming, Jr., MD
Scott R. Gerst, MD
Athanasios P. Glekas, PhD
Ravinder K. Grewal, MD
Sofia S. Haque, MD
Bob L. Hou, PhD
Sinchun Hwang, MD
Sandra Joo, MD
Jennifer B. Kaplan, MD
Sasan Karimi, MD
Anuradha Khilnani, MD
Yuliya Lakhman, MD
Jonathan Landa, DO
Robert A. Lefkowitz, MD
Duan Li, MD
John K. Lyo, MD

INSTRUCTORS
James L. Fuqua III, MD
David H. Gultekin, PhD
Seth Stephen Katz, MD, PhD

Weining Ma, MD
Majid Maybody, MD
Yousef Mazaheri, PhD
Michael R. McDevitt, PhD
Svetlana Mironov, MD
Neeta Pandit-Taskar, MBBS
Kyoung K. Peck, PhD
Nagavarakishore Pillarsetty, PhD
Vladimir Ponomarev, MD, PhD
Jurgen Rademaker, MD
Elmer B. Santos, MD, PhD
Debra M. Sarasohn, MD
Sunita Bai Thakur, PhD
Raymond H. Thornton, MD
Rachel S. Title, MD
Darren R. Veach, PhD
Robert J. Young, MD
Jingbo Zhang, MD
DEPARTMENT OF SURGERY

CHAIR AND ATTENDING
Peter T. Scardino, MD
David H. Koch Chair

DIVISION HEAD AND ATTENDING
Ronald P. DeMatteo, MD
Division of General Surgical Oncology

ATTENDINGS
David H. Abramson, MD
Manjit S. Bains, MD
Neil H. Bander, MD
Richard R. Barakat, MD
Ronald O. Perelman Chair in Gynecologic Surgery
Leslie H. Blumgart, MD
Enid A. Haupt Chair in Surgery
Mercedes Castiel, MD
Hiram S. Cody III, MD
Daniel G. Coit, MD
Peter G. Cordeiro, MD
Guido Dalbagni, MB, ChB
James A. Eastham, MD
Yuman Fong, MD
Murray F. Brennan Chair in Surgery
Harold P. Freeman, MD
José G. Guillem, MD
Bertrand Guillonneau, MD
John H. Healey, MD
Harry W. Herr, MD
William J. Hoskins, MD
Joseph M. Huryn, DDS
William R. Jarnagin, MD
Maureen Killackey, MD
Dennis H. Kraus, MD
Michael P. La Quaglia, MD
Hans G. Lilja, MD
Monica Morrow, MD
Anne Burnett Windfohr Chair of Clinical Oncology
John P. Mulhall, MD
Raul O. Parra, MD
Philip B. Paty, MD
Valerie W. Rush, MD
William G. Cahan Chair in Surgery
Paul Russo, MD
Virgilio Sacchini, MD
Lisa M. Scalfani, MD
Jatin P. Shah, MD
Elliot W. Strong Chair in Head and Neck Oncology
Ashok R. Shaha, MD
Joel Sheinfeld, MD
Samuel Singer, MD
Pramod C. Sogani, MD
Diane E. Stover, MD
Kimberly J. Van Zee, MD
E. Darracott Vaughan, MD
Dorothy A. White, MD
W. Douglas Wong, MD
Stuart H. Quan
Chair in Colorectal Surgery

ASSOCIATE ATTENDINGS
Nadeem R. Abu-Rustum, MD
Peter J. Allen, MD
Edward A. Athanasiadis, MD
Oheneba Boachie-Adjei, MD
Bernard H. Bochner, MD
Jay O. Boyle, MD
Mary S. Brady, MD

Carol L. Brown, MD
Deborah M. Capko, MD
Dennis S. Chi, MD
Michael D’Angelica, MD
Joseph J. Disa, MD
S. Machele Donat, MD
Robert J. Downey, MD
Cheryl L. Estilo, DMD
Raja M. Flores, MD
Mary L. Gemignani, MD
Henry G. Godfrey, MD
Alexandra S. Heerdt, MD
Mark-Hein Heinemann, MD
Noah D. Kauff, MD
Vincent Laudone, MD
Ross T. Lyon, MD
Babak J. Mehrara, MD
Alexis L. Montgomery, MD
Carol D. Morris, MD
Snehal Patel, MBBS
Sitaram Pillarisetty, MD
Glenn L. Schattman, MD
Bhuvanesh Singh, MD
Yukio Sonoda, MD
Larissa K. F. Temple, MD
Martin R. Weiser, MD
Richard J. Wong, MD

ASSISTANT ATTENDINGS
Prasad S. Adusumilli, MBBS
Charlotte E. Artyian, MD, PhD
George C. Athanasiadis, MD
Ryan C. Branski, PhD
Jeanne Carter, PhD
Brett S. Carver, MD
Mehmet Civelek, MD
Jonathan A. Coleman, MD
David J. Finley, MD
Ian Ganly, MB, ChB, PhD
Ginger J. Gardner, MD
Leonard N. Girardi, MD
Deborah J. Goldfrank, MD
Allan D. Greenberg, DMD, PhD
Jerry L. Halpern, DDS
James Huang, MD
John Karwowski, MD
K. Craig Kent, MD
Tari A. King, MD
Jeanne A. Petrek Junior Faculty Chair
Leonard Y. Lee, MD
Mario M. Leitao, Jr., MD
Douglas A. Levine, MD
John P. Lyden, MD
Charles A. Mack III, MD
Debra A. Mangino, DO
Brian P. Marr, MD
Colleen M. McCarthy, MD
Garrett Nash, MD
Bernard J. Park, MD
Elisa R. Port, MD
Andrea L. Pusic, MD
Farhang Rabbani, MD
Nabil Rizk, MD
Jaspreet S. Sandhu, MD
Nitsana A. Spigland, MD
Vivian E. Mack Strong, MD
Karim A. Touijer, MD
Steven J. Tunick, DMD
Zhaoshi Zeng, MD, MPH

HUMAN ONCOLOGY AND PATHOGENESIS PROGRAM

CHAIR AND ATTENDING
Charles L. Sawyers, MD
Marie-Josée and Henry R. Kravis Chair in Human Oncology and Pathogenesis; Howard Hughes Medical Institute Investigator

ATTENDINGS
James A. Fagin, MD
Marc Ladanyi, MD

ASSOCIATE ATTENDING
Adriana Heguy, PhD

ASSISTANT ATTENDINGS
Timothy A. Chan, MD, PhD
Ross L. Levine, MD
Geoffrey Beene Junior Faculty Chair
Ingo K. Mellinghoff, MD
William Pao, MD, PhD
Miner Family Chair in Intrathoracic Cancers
David B. Saltz, MD
Elizabeth and Felix Rohatyn Chair for Junior Faculty
Lauren Kushner, PNP, RN
Patricia Lakin, WHNP, RN
Mary Layman-Goldstein, ANP, RN
Angela Lentini-Rivera, PNP, RN
Nicole R. Leonhart, ANP, RN
Isobel M. Lewis, ANP, RN
Christine A. Liebertz, ANP, RN
Yi-Chih Lin, PNP, RN
Camille L. Lineberry, NP, RN
Chhiu-Mei Liu, NP, RN
Marie-Helene Lofland, NP, RN
Amy E. Logue, ANP, RN
Helen M. Loumeau, ANP, RN
Andria Lyn, ACNP, RN
Peggy Lynch, FNP, RN
Noelia Maamouni, ANP, RN
Carrie Marshall, ANP, RN
Marie Kathlyn Marte, ANP, RN
Leslie V. Matthews, ANP, RN
Shirley Maaszoul, ANP, RN
Emily J. McCullagh, FNP, RN
Christine McGrae, ANP, RN
Katen McGuire, PNP, RN
Julie Ellen McMahon, ANP, RN
Julianne McNamara, FNP, RN
Margaret McSweeney, ACNP, RN
Carol Ann Milazzo-Kiedaisch, FNP, RN
Aida Miletic, FNP, RN
Mary Montefusco, ACNP, RN
Joanna Moulton, PNP, RN
Kara Ann Muhr, NP, RN
Joseph B. Narus, ANP, RN
Rachel O. Nebab, NP, RN
Christina Anne O’Connor, ANP, RN
Katherine G. O’Connor, PNP, RN
MaryAnn P. O’Connor, FNP, RN
Lauren Oelkers-Baker, ANP, RN
Kristen Ohagan, ANP, APRN, RN
Shannon O’Keefe, NP, RN
Marykate O’Rourke, NP, RN
Claudia M. Ortiz, WHNP, RN
Rosemary Ortiz, FNP, RN
Maria Pacis, ANP, RN
Alicia L. Paton, NP, RN
Ashley Pereira, NP, RN
Mary C. Petriccione, FNP, RN
Sandra Pezzulli, CRNP, RN
Mary Katherine Plakovik, NP, RN
Joan M. Pope, FNP, RN
Elaine M. Pottenger, GNP, RN
Nana Prempeh-Kete Ku, ANP, RN
Erin Punturieri, ANP, RN
Avery Puttermann, NP, RN
Hilda Quintanilla, ANP, RN
Robin Rawlins-Duell, ANP, RN
Tara Reilly, NP, RN
Rebecca W. Repetti, NP, RN
Carol Rossetto, ANP, RN
Mary Rudzwick, ANP, RN
Tara Russo, FNP, RN
Lina Saab, FNP, RN
Anita Schabel, FNP, RN
Mary A. Schoen, ANP, RN
Lauren Scoma, NP, RN
Sharlene Seecharran, ACNP, RN
Twilight Seward, NP, RN
Yelena Shames, ACNP, RN
Rosanne Sharp, FNP, RN
Ana Sjoberg, ANP, RN
Zeta Smilke-Hamilton, ANP, RN
Tammy Son, ACNP, RN
Celeste M. Springer, ANP, RN
Deborah Stein, NP, RN
Emily Storey, NP, RN
Denise Striffiler, ACNP, RN
Dyana Sumner, CRNP, RN
Yekaterina Tavayan, ACNP, RN
Patricia M. Telford, ANP, RN
Ursula McPeak Tomlinson, PNP, RN
Joanne E. Torok-Castanza, ANP, RN
Kathleen A. Trotta, ANP, RN
Roseann Tucci, FNP, RN
Leslie Tyson, CRNP, RN
Jill Vanak, CRNP, RN
Stephanie Vitolano, PNP, RN
Jamie Jennifer Voccola, PNP, RN
Kathy Vukasanaj, ANP, RN
Christine D. Waters-Clayton, ANP, RN
Richard Weiner, NP, RN
Joanne M. Wells, ANP, RN
Elizabeth H. Whittam, FNP, RN
Christina M. Wray-Asaro, PNP, RN
Fengxin Wu, PNP, RN
Jane Yoffe, FNP, RN
Heidi Yulico, NP, RN
Nicole Zakak, NP, RN
Joan M. Zatcky, ANP, RN

DIVISION OF PHARMACY SERVICES

SUPERVISORS
Nelly Adel, RPh
Jerry Chow, RPh
Jacqueline Gomes, RPh
Susan Munillo, RPh
Donald Murphy, RPh
Gerald O’Neill, RPh
Marie Ryan, RPh
Cathy Sender, RPh
Faina Shenderov, RPh
John Timoney, RPh
Elaine Yam, RPh
Karen Yeung, RPh

CLINICAL COORDINATORS
Stern Bereth, RPh
Manpreet Boparai, RPh
Amelia Chan, RPh
Florina Chuy, RPh
Joseph Galgano, RPh
Dennis Grossano, RPh
Michael Kellick, RPh
Mark Klang, RPh
Caroline Lau, RPh
Melissa Lee-Teh, RPh
Diane Leone, RPh
Donna McGuffy, RPh
Vivian Park, RPh
Barbara Simon, RPh
Pofan Sin, RPh
Gregory Stelzer, RPh
Frank Surita, RPh
Edward Tyler, RPh
Frank Zappa, RPh
Anthony Zinga, RPh

CLINICAL SPECIALISTS
Nina Cohen, RPh
Stephen Harnicar, RPh
Sherry Mathew, RPh
Jeanna Miller, RPh
Alla Paskovaty, RPh
Richard Tizou, RPh

DIRECTOR
Charles D. Lucarelli, RPh

ASSOCIATE DIRECTORS
Stella Lee Eng, RPh
Scott Freeswick, RPh
Raymond J. Muller, RPh
Priti Patel, RPh

DIRECTOR
Jane Bowling, DSW, LCSW

DIVISION OF SOCIAL WORK

SOCIAL WORK SENIOR STAFF
Diane Iannuzzi, LCsw
Rosalind Kleban, LCSW
Anne Martin, PhD, LCSW

POST-TREATMENT RESOURCE PROGRAM
Penny Damaskos, LCSW
STEERING COMMITTEE

James P. Allison, PhD
Kathryn V. Anderson, PhD
Eric M. Cottington, PhD
John R. Gunn
Alan Hall, PhD
Kenneth J. Marians, PhD
Joan Massagué, PhD
Nikola P. Pavletich, PhD
Chris Sander, PhD
David A. Scheinberg, MD, PhD
Harold Varmus, MD (ex officio)

DIRECTOR
Thomas J. Kelly, MD, PhD
Benno C. Schmidt Chair
of Cancer Research

CANCER BIOLOGY AND GENETICS PROGRAM

CHAIR AND MEMBER
Joan Massagué, PhD
Alfred P. Sloan Chair;
Howard Hughes Medical Institute Investigator

MEMBERS
Robert Benezra, PhD
Eric C. Holland, MD, PhD
Emily Tow Jackson Chair in Oncology
Harold Varmus, MD

ASSOCIATE MEMBERS
Johanna A. Joyce, PhD
Geoffrey Beene Junior Faculty Chair
Anna M. Kenney, PhD
Robert J. Klein, PhD
Andrea Ventura, MD, PhD
Geoffrey Beene Junior Faculty Chair
Hans G. Wendel, MD

Professional Support Staff
LABORATORY MEMBERS
Neil S. Lipman, VMD
Felix R. Wolf, DVM, PhD

ASSOCIATE LABORATORY MEMBER
Andrew C. Nicholson, DVM, PhD
ASSISTANT LABORATORY MEMBERS
Paul C. Ezell, DVM
Sebastian Monette, DVM

Joint Appointment
Kenneth Offit, MD

CELL BIOLOGY PROGRAM

CHAIR AND MEMBER
Alan Hall, PhD
Alfred P. Sloan Chair

MEMBERS
Raju S. K. Chaganti, PhD
William E. Snee Chair
Filippo G. Giancotti, MD, PhD
Paul A. Marks, MD
Malcolm A. S. Moore, DPhil
End A. Haupt Chair of Cell Biology
Marilyn D. Resh, PhD
Urs Rutishauser, PhD

ASSISTANT MEMBERS
Xuejun Jiang, PhD
Catherine and Frederick R. Adler Chair for Junior Faculty
Jidong Liu, PhD
Michael H. Overholtzer, PhD
Meng-Fu Bryan Tsou, PhD

Professional Support Staff
ASSOCIATE LABORATORY MEMBER
Margaret A. Leversha, PhD

At The Rockefeller University
ASSISTANT MEMBER (AFFILIATE)
Hironori Funabiki, PhD

At Weill Cornell Medical College
MEMBER (AFFILIATE)
Timothy A. Ryan, PhD

COMPUTATIONAL BIOLOGY PROGRAM

CHAIR AND MEMBER
Chris Sander, PhD
Tri-Institutional Professor

ASSISTANT MEMBERS
Gregoire Altan-Bonnet, PhD
Christina S. Leslie, PhD
Franziska Michor, PhD

Professional Support Staff
LABORATORY MEMBER
Alex E. Lash, MD

ASSISTANT LABORATORY MEMBER
Nicholas D. Socci, PhD

At Cornell University
ASSISTANT MEMBER (AFFILIATE)
Uri Keich, PhD

At The Rockefeller University
MEMBER (AFFILIATE)
Stanislas Leibler, PhD

At Weill Cornell Medical College
MEMBER (AFFILIATE)
Harel Weinstein, DSc
**DEVELOPMENTAL BIOLOGY PROGRAM**

**CHAIR AND MEMBER**  
Kathryn V. Anderson, PhD  
Enid A. Haupt Chair in Developmental Biology

**MEMBERS**  
Mary K. Baylies, PhD  
Peter Besmer, PhD  
Maria Jasin, PhD  
William E. Snee Chair  
Alexandra L. Joyner, PhD  
Courtney Steel Chair in Pediatric Cancer Research  
Elizabeth H. Lacy, PhD

**ASSOCIATE MEMBER**  
Lorenz P. Studer, MD

**ASSISTANT MEMBERS**  
Zhirong Bao, PhD  
Anna-Katerina Hadjantonakis, PhD  
Julia A. Kaufschmidt, PhD  
Eric C. Lai, PhD  
Song-Hai Shi, PhD  
Jennifer A. Zallen, PhD

**Professional Support Staff**  
LAWERSOULARY MEMBERS  
Katia O. Manova-Todorova, PhD  
Willie H. Mark, PhD

**ASSISTANT LABORATORY MEMBER**  
Mark J. Tomishima, PhD  
Frank A. Howard Scholar  
Nicholas Tolwinski, PhD

**IMMUNOLOGY PROGRAM**

**CHAIR AND MEMBER**  
James P. Allison, PhD  
David H. Koch Chair in Immunologic Studies; Howard Hughes Medical Institute Investigator

**MEMBERS**  
Bo Dupont, MD, DSc  
Ulrich G. Hämmerling, PhD  
Alan N. Houghton, MD  
Virginia and Daniel K. Ludwig Clinical Chair  
Herbert F. Oettgen, MD  
Lloyd J. Old, MD  
William E. Snee Chair of Cancer Immunology; Director, New York Branch of Ludwig Institute for Cancer Research  
Richard J. O'Reilly, MD  
Claire L. Tow Chair in Pediatric Oncology Research  
Eric G. Palmer, MD  
Enid A. Haupt Chair in Clinical Investigation

**ASSOCIATE MEMBERS**  
Lisa K. Denzin, PhD  
Michael S. Glickman, MD  
Catherine and Frederick R. Adler Chair for Junior Faculty  
Derek B. Sant'Angelo, PhD

**ASSISTANT MEMBERS**  
Jayanta Chaudhuri, PhD  
Frederick R. Adler Chair for Junior Faculty  
Morgan Huse, PhD  
Ming Li, PhD

**Professional Support Staff**  
ASSOCIATE LABORATORY MEMBERS  
P. Jan Hendrikx, PhD  
Frances Weiss-Garcia, PhD

**ASSISTANT LABORATORY MEMBERS**  
Annamalai Selvakumar, PhD  
Jianda Yuan, MD, PhD

**Joint Appointments**  
Ronald P. DeMatteo, MD  
Katharine C. Hsu, MD, PhD  
Jedd D. Wolchok, MD, PhD

**MOLECULAR BIOLOGY PROGRAM**

**CHAIR AND MEMBER**  
Kenneth J. Marians, PhD  
William E. Snee Chair

**MEMBERS**  
Jerard Hurwitz, PhD  
Scott N. Keeney, PhD  
Howard Hughes Medical Institute Investigator  
Thomas J. Kelly, MD, PhD  
Brent C. Schmidt Chair of Cancer Research  
Andrew Koff, PhD  
John H. J. Petrini, PhD  
Paul A. Marks Chair in Molecular Cell Biology  
Mark S. Ptashne, PhD  
Virginia and Daniel K. Ludwig Chair

**ASSOCIATE MEMBER**  
Prasad V. Jallepalli, MD, PhD

**ASSISTANT MEMBERS**  
Iestyn Whitehouse, PhD  
Xiaolan Zhao, PhD

**Professional Support Staff**  
ASSOCIATE LABORATORY MEMBERS  
Hedyi Erdjument-Bromage, PhD  
Ricardo Toledo-Crow, PhD  
Agnès Viale, PhD

**ASSISTANT LABORATORY MEMBER**  
Mariana M. Yaneva, PhD

**At The Rockefeller University**  
MEMBER (AFFILIATE)  
C. David Allis, PhD

**Joint Appointment**  
Simon N. Powell, MBBS, PhD  
Enid A. Haupt Chair in Radiation Oncology
MOLECULAR PHARMACOLOGY AND CHEMISTRY PROGRAM

CHAIR AND MEMBER
David A. Scheinberg, MD, PhD
Vincent Astor Chair

MEMBERS
Colin B. Begg, PhD
Eugene W. Kettering Chair
Ronald G. Blasberg, MD
Benno C. Schmidt Chair in Clinical Oncology
Bayard D. Clarkson, MD
Enid A. Haupt Chair of Therapeutic Research
Samuel J. Danishefsky, PhD
Eugene W. Kettering Chair

Zvi Fuks, MD
Alfred P. Sloan Chair
David Y. Gin, PhD
Hedvig Hricak, MD, PhD
Carroll and Milton Petrie Chair
Richard N. Kolesnick, MD
Steven M. Larson, MD
Donna and Benjamin M. Rosen Chair in Radiology
C. Clifton Ling, PhD
Enid A. Haupt Chair of Medical Physics
Stephen D. Nimer, MD
Alfred P. Sloan Chair
Gavriil W. Pasternak, MD, PhD
Anne Burnett Tandy Chair of Neurology
Jerome B. Posner, MD
American Cancer Society Clinical Research Professor; George C. Cotzias Chair of Neuro-Oncology

Neal Rosen, MD, PhD
Enid A. Haupt Chair in Medical Oncology
Michel Sadelain, MD, PhD
Stephen and Barbara Friedman Chair
Peter T. Scardino, MD
David H. Koch Chair

ASSOCIATE MEMBERS
Yueming Li, PhD
Derek S. Tan, PhD

ASSISTANT MEMBERS
Luca Cartegni, PhD
Gabriela Chiossi, PhD
Frederick R. Adler Chair for Junior Faculty
Minkui Luo, PhD

Professional Support Staff
LABORATORY MEMBERS
Ting-Chao Chou, PhD
Hakim Djaballah, PhD

ASSOCIATE LABORATORY MEMBERS
Ouathek Ouerfelli, PhD
Isabelle Rivière, PhD
George D. Sukcnick, PhD
Nian Wu, PhD

ASSISTANT LABORATORY MEMBERS
Elisa de Stanchina, PhD
Ying-Xian Pan, PhD
Maria K. Spassova, PhD

At Cornell University
ASSISTANT MEMBERS (AFFILIATE)
Hening Lin, PhD
Jon T. Njardarson, PhD

At The Rockefeller University
ASSISTANT MEMBER (AFFILIATE)
Sean Brady, PhD
Joint Appointment
Jason A. Koutcher, MD, PhD
Jason S. Lewis, PhD

STRUCTURAL BIOLOGY PROGRAM

CHAIR AND MEMBER
Nikola P. Pavletich, PhD
Stephen and Barbara Friedman Chair; Howard Hughes Medical Institute Investigator

MEMBERS
Jonathan D. Goldberg, PhD
Stephen and Barbara Friedman Chair; Howard Hughes Medical Institute Investigator
Christopher D. Lima, PhD
Dimitar B. Nikolov, PhD
Dinshaw Patel, PhD
Abby Rockefeller Mauzé Chair of Experimental Therapeutics

ASSISTANT MEMBER
Stephen B. Long, PhD

Professional Support Staff
ASSOCIATE LABORATORY MEMBERS
Yehuda Goldgur, PhD
David M. Zuckerman, BSEE

ASSOCIATE LABORATORY MEMBERS
Hening Lin, PhD
Jon T. Njardarson, PhD

At Cornell University
ASSISTANT MEMBERS (AFFILIATE)
Sean Brady, PhD
Joint Appointment
Jason A. Koutcher, MD, PhD
Jason S. Lewis, PhD
MEMBERS EMERITI
MEMORIAL SLOAN-KETTERING CANCER CENTER

Lowell L. Anderson, PhD
Donald Armstrong, MD
June L. Biedler, PhD
Ronald A. Castellino, MD
E. Eugene Covington, MD
Jack J. Fox, PhD
Joseph H. Gallicich, Jr., MD
Robert B. Golbey, MD
Walter B. Jones, MD
John L. Lewis, Jr., MD
Philip H. Lieberman, MD

Kenneth O. Lloyd, PhD
Klaus Mayer, MD
W. P. Laird Myers, MD
Stuart H. Q. Quan, MD
Richard A. Rifkind, MD
Lawrence N. Rothenberg, PhD
F. Kingsley Sanders, DPhil
Morton K. Schwartz, PhD
Maurice E. Shils, MD, ScD
Francis M. Sirotnak, PhD
Martin Sonenberg, MD, PhD

Maus W. Stearns, MD
Stephen S. Sternberg, MD
C. Chester Stock, PhD
Elliot W. Strong, MD
Osias Stutman, MD
Alan D. Turnbull, MD
Norma Wollner, MD
James M. Woodruff, MD
Samuel D. J. Yeh, MD, ScD
**Chairman of the Board**
Louis V. Gerstner, Jr.

**President**
Harold Varmus, MD

**Provost**
Thomas J. Kelly, MD, PhD

**Treasurer**
John R. Gunn

**Trustees**
Richard I. Beattie
Richard N. Foster
Stephen Friedman
Louis V. Gerstner, Jr.

**Dean**
Kenneth J. Marians, PhD

**Assistant Treasurer**
Michael P. Gutnick

**Trustees**
Jonathan N. Grayer
David H. Koch
Benjamin M. Rosen

**Associate Dean**
Gita Bosch, PhD

**Secretary**
Carolyn Bonheur

---

**Sloan-Kettering Division,**
**Weill Cornell Graduate School of Medical Sciences**

**Director**
Thomas J. Kelly, MD, PhD

**Director, Graduate Studies**
Kenneth J. Marians, PhD

**Graduate Program Co-Chairs**

<table>
<thead>
<tr>
<th>Unit</th>
<th>Chair</th>
<th>Co-Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biochemistry and Structural Biology Unit</td>
<td>Nikola P. Pavletich, PhD</td>
<td>Cell Biology and Genetics Unit</td>
</tr>
<tr>
<td>Molecular Biology Unit</td>
<td>Stewart Shuman, MD, PhD</td>
<td>Pharmacology Unit</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Immunology Unit</td>
</tr>
</tbody>
</table>

---

**2008 Annual Report**

68
Work on the floors, framework, and façade of the seven-story structure that constitutes Phase II of the Mortimer B. Zuckerman Research Center (ZRC) continued in 2008 and will be completed in 2009. Once this is finished, work will be suspended and the interior floors will be fitted out at a future date. The new building will complete the ZRC and is expected to house conference facilities, a 350-seat auditorium, office space, and dry laboratories.

Construction progressed on Phase II of the ZRC.

In 2008, work continued on the interior of the new 16-story Breast and Imaging Center, on Second Avenue between 65th and 66th Streets, which contains the expanded Evelyn H. Lauder Breast Center. Eleven floors are expected to be completed by the summer of 2009, with the remaining five floors — planned for academic space — to be ready at a later date. The building will house a range of important MSKCC initiatives, including a diagnostic imaging center, and will open for patients in the fall of 2009.

(From left) Exterior view of the Breast and Imaging Center seen from Second Avenue and 66th Street; the center’s interior will accommodate clinical space and academic offices.
Cash gifts for the year totaled $315.4 million, the most in Memorial Sloan-Kettering’s history and two-and-a-half times the amount received in 2002, the first year of the Campaign. This strong forward momentum will be essential in the months to come, as Memorial Sloan-Kettering seeks to generate critical new support in the midst of a global economic downturn. Under the leadership of Co-Chairs Douglas A. Warner III and Louis V. Gerstner, Jr., the Campaign will continue to spotlight the vital role of philanthropy in helping to drive future breakthroughs in understanding and treating cancer.

Moving ahead, they and the entire Memorial Sloan-Kettering community find inspiration in the generosity of the Center’s benefactors, including those who made the following large commitments during the past year:

- The gift of a membership interest in Geoffrey Beene, LLC, brings total contributions from various entities associated with the celebrated fashion designer to $101.9 million. These funds are being used to underwrite the Geoffrey Beene Cancer Research Center, which was established in 2006 with support from the Estate of Geoffrey Beene. It brings together researchers and physicians from the Human Oncology and Pathogenesis Program and the Cancer Biology and Genetics Program to pursue a range of activities aimed at translating the latest scientific breakthroughs into new approaches to patient care.

The generosity shown by thousands of contributors to the Campaign for Memorial Sloan-Kettering helped make 2008 the Center’s best fundraising year ever. As of December 31, the Campaign had recorded more than $1.82 billion in gifts and pledges, bringing it within sight of its $2 billion target with three years still to go.
• A $5 million commitment from Louis V. Gerstner, Jr., through his foundation will help support a new generation of promising cancer scientists at a critical early stage in their careers. The Louis V. Gerstner, Jr. Young Investigators Fund assists exceptional men and women who have already demonstrated their commitment to careers in science; it responds directly to a crisis in funding at the NIH that has severely constrained the agency’s grant-making ability, with young investigators being especially hard-hit. This latest commitment from Mr. Gerstner brings his total Campaign giving to more than $20 million.

• Michael A. and Zena Wiener have pledged $5 million for a new research initiative designed to promote significant progress in understanding and treating bladder cancer. With its goal of putting laboratory discoveries to work for patients, the Michael A. and Zena Wiener Research and Therapeutics Program in Bladder Cancer is focused on the development of new tools and techniques for detecting the disease at the earliest possible stage and for targeting each patient’s tumor with individualized therapies.

• With his commitment of $3 million to establish an endowed position for a senior faculty member, Board member David H. Koch has increased his total giving to the Campaign to nearly $45 million. The new David H. Koch Chair is the latest in a series of gifts — including the creation of the David H. Koch Center for the Immunological Control of Cancer and support for prostate cancer research — that together reflect the breadth of Mr. Koch’s interests and the extraordinary impact he has had on Memorial Sloan-Kettering.

• The Bristol-Myers Squibb Foundation has committed $3 million to create two endowed positions for talented young investigators, to be known as the Bristol-Myers Squibb/James D. Robinson III Junior Faculty Chairs. The gift, which recognizes Mr. Robinson’s service as a leader of the Bristol-Myers Squibb Company and as Honorary Chairman of Memorial Sloan-Kettering’s Boards of Overseers and Managers, comes on top of an earlier commitment from the Foundation to support the Bioinformatics Core Facility.

• Bequests and other planned gifts continued to provide a significant source of support for the Center in 2008. Memorial Sloan-Kettering received $4.5 million from the Estate of Charles J. Mauro, to be divided evenly between translational research and a fund that will assist patients who are unable to pay for their care, in many cases because their insurance has run out. In addition, funds directed to Memorial Sloan-Kettering under the Trust of the late Elizabeth Frelinghuysen will provide $3.5 million in unrestricted support, assuring the Center of crucial flexibility in meeting needs as they arise.

Many dedicated friends of Memorial Sloan-Kettering have put their energy and enthusiasm to work in support of the Center’s mission through their participation in special athletic events. A total of 689 runners took part in the 2008 ING New York City Marathon as members of Fred’s Team, in the process generating support for a range of research initiatives. In all, Fred’s Team raised nearly $3.6 million for the Center last year.

In June, the second annual Rock & Run on the River drew an estimated 4,000 participants for a 5K walk/run and celebration of cancer survivorship that benefited Memorial Sloan-Kettering’s Cancer Survivorship Initiative. Also helping to boost public awareness about the work being done at Memorial Sloan-Kettering was tennis star James Blake, who announced plans to honor his late father through the creation of the Thomas Blake, Sr., Memorial Research Fund. The fund is raising money for research into early detection and screening through a merchandise program, a charity tennis exhibition, and other activities.

As the Campaign for Memorial Sloan-Kettering enters its final phase, the resources it attracts will play an increasingly important role in confronting the complex challenges posed by cancer. The Campaign will continue paving the way to future breakthroughs with the encouragement of benefactors whose gifts, both large and small, have had such an enormous impact so far.
<table>
<thead>
<tr>
<th>Amount Range</th>
<th>Philanthropies</th>
</tr>
</thead>
<tbody>
<tr>
<td>$25,000,000 or More</td>
<td>The Atlantic Philanthropies, The Estate of Geoffrey Beene, Mr. and Mrs. Jack Byrne and The Byrne Foundation, Mr. and Mrs. William H. Goodwin, Jr., and the Commonwealth Foundation for Cancer Research, The Sidney Kimmel Foundation, David H. Koch, The Leonard and Evelyn Lauder Charitable Trust, Inc., Mortimer B. Zuckerman</td>
</tr>
<tr>
<td>$20,000,000 — $24,999,999</td>
<td>Anonymous, The Louis V. Gerstner, Jr. Foundation, Inc.</td>
</tr>
<tr>
<td>$10,000,000 — $19,999,999</td>
<td>Trust of Burton Abrams, Stanley F. and Fiona Druckenmiller, The Stephen and Barbara Friedman Foundation, The Arnold and Arlene Goldstein Family Foundation, Prostate Cancer Foundation, Robertson Foundation, Laurance S. Rockefeller, Robert F.X. Sillerman and Laura Baudo Sillerman through their Tomorrow Foundation, Simons Foundation, Mr. and Mrs. Douglas A. Warner III</td>
</tr>
</tbody>
</table>
General Electric Company
Eileen Genet Fund for Ovarian Cancer Research and Prevention
Trust of Josephine A. Gilmore
Estate of Anna H. Gleason
Miriam and Alan Goldberg
Golfers Against Cancer Foundation
The Gordon Fund
Trust of Jane H. Gordon
Jonathan N. Grayer
The Marion and Louis Grossman Foundation
Mr. and Mrs. Robert Grossman
Trust of Helen Guerin
Hackers for Hope
Mr. and Mrs. James J. Hagan
Mr. and Mrs. John J. Hannan
Estate of Margaret H. Hanson
Stephen P. Hanson
Jamie and Jeffrey Harris
Mr. and Mrs. Norman Hascoe
The Lita Annenberg Hazen Foundation
Mr. and Mrs. Benjamin W. Heineman, Jr.
Marie B. Hilliard
The Charles and Marjorie Holloway Foundation, Inc.
Estate of Dorris Hutchison
Trust of Harry C. Jaecker, Jr.
Estate of Wilda Johnson
Mr. and Mrs. Matania Kochavi
Estate of Rosemarie Krulish
The Thomas G. Labrecque Foundation
Estate of Ada Leventhal
Dr. Nancy Alpern Levin
The LisaBeth Foundation
The Litzin Foundation
Robert S. Ludwig and Gwyneth E. Rankin
Lydian Asset Management, LP
The Lymphoma Foundation
The Maloris Foundation
Trust of Estelle A. Manning
Margaux’s Miracle Foundation
The G. Harold & Leila Mathers Foundation
Mrs. William L. Matheson
Melanoma Research Alliance Foundation
Merrill Lynch & Co. Foundation, Inc.
Fred and Marie-Noelle Meyer
Estate of Warren A. Montel
MSKCC Thrift Shop
Musheft Family Foundation, Inc.
The Samuel I. Newhouse Foundation
Stavros S. Niarchos Foundation
The Olayan Group
John and Francie Pepper
Estate of Jeanne Poli
Laura and Christopher A. Pucillo
Charles H. Revison Foundation
The Robbins Family Foundation
The Jim & Linda Robinson Foundation
The Felix and Elizabeth Rohatyn Foundation
The Laura Rosenberg Foundation, Inc.
Estate of Lillian E. Rosenmerkel
Juliet Rosenthal Foundation, Inc.
Jack Rudin
The Louis & Rachel Rudin Foundation
The May & Samuel Rudin Family Foundation
The Peter M. Sacerdote Foundation
Lewis A. Sanders
Faye Sarofim & Co.
Estate of Margaret W. Schafer
Mr. and Mrs. Norman C. Selby
Trust of Henry H. Shepard
Alfred J. and Stephanie Shuman through the Windmill Lane Foundation
Mr. and Mrs. Herbert J. Siegel
The Rosanne H. Silbermann Foundation
The Paul Singer Family Foundation
The Skirball Foundation
Trust of William Kirkland Smith
Trust of Clemence and Edwin Snyder
The Society of MSKCC
The Special Projects Committee of The Society of MSKCC
Estate of Stanley R. Stones
Mr. and Mrs. David K. Storrs
George Strawbridge, Jr.
The Margaret Dorrance Strawbridge Foundation
Foundation of PA
The Jeffrey Steiner Family Foundation
Trust of M. Allen Swift
Tarnopol Family Foundation
Estate of Lillian Tomek
Anthony and Carole Trapani
The Trump Group
Universal Network Television
The V Foundation
Joan and Sanford I. Weill
Louis and Jane Weinstock
The Lillian S. Wells Foundation, Inc.
Mr. and Mrs. Clay T. Whitehead
Estate of Carolyn H. Wilson
Winterburn Foundation
Mrs. W. Wister, Jr.
Mr. and Mrs. Robert Wright

$500,000 — $999,999
Estate of Marguerite Abrams
Allen & Company, Inc.
Anonymous
Roland Arthur
Associates Committee of The Society of MSKCC
Aventis Pharmaceuticals, Inc.
Mr. and Mrs. Robert C. Baker
Family Foundation
Estate of Eileen W. Bamberger
Trust of William T. Benett
Betty, James, and Thomas Blake (The Thomas Blake, Sr. Memorial Fund)
Trust of Etheleva Boehme
Estate of William Boehme
Trust of Frederick W. Bonacker, Jr.
The Andrea and Charles Bronfman Philanthropies, Inc.
The Cancer Research Foundation of America
Estate of Richard B. Carman
Trust of Betty R. Ciafone
Citigroup
Estate of Harry J. Colish
The Connecticut Sports Foundation
Constant Convocation Center
The Elaine Terner Cooper Foundation
Trust of Faye Copeland
Estate of Helen M. Cramer
The Irma L. and Abram S. Croll Charitable Trust
Cure Breast Cancer Foundation, Inc.
The Dana Foundation
Davis Enterprises
Estate of Sandra Newman Dawson
The DeGroot Family Foundation
Deutsche Bank Securities Inc.
The Entertainment Industry Foundation
Mr. and Mrs. David Epstein
Arthur Falcone
Trust of Harold P. Farrington
Estate of Alice H. Fich
Trust of Alice D. Feider
Trust of Marie Finch
The Michael J. Fox Foundation
The Fund for Ophthalmic Knowledge
Estate of Joseph G. Gaumont
Estate of Lillian B. George
The Gerber Foundation
Estate of Thelma Gish
The Horace W. Goldsmith Foundation
The Mark Haas Foundation
Mr. and Mrs. William W. Haerther, Jr.
Estate of Ethel V. Haldeman
Evelyn A. J. Hall Charitable Trust
Mr. and Mrs. William B. Harrison, Jr.
The Hecksher Foundation for Children
Estate of Ruth H. Hewlett
Marie B. Hilliard
Deanne and Arthur Indursky
Johnson & Johnson
Estate of Horace A. Jones
Trust of Marion Kahn
Fritz and Adelaide Kaufmann Foundation
Kinetics Foundation
Estate of Joan E. Kinley
Estate of Ruth Koch
The Koodish Family Charitable Trust
Trust of Grace Fay Lamb
The Jacob & Valeria Langeloth Foundation
Philippe Laub
Estate of Wilhelmina LeLeune
Harold F. Levinson
Life Raft Group
Trust of Martin C. and Margaret V. Lohsen
The Lustgarten Foundation for Pancreatic Cancer Research
Estate of Lucille Knowles Freedman Mann
Mr. and Mrs. Joseph L. Martino
Trust of John C. McCormick
Estate of Ralph Melson
J.P. Morgan Chase
The Norman M. Morris Foundation
The William T. Morris Foundation
The New York Community Trust
The Sylvan and Ann Oestreich Foundation
Trust of Jo Anne H. Olmstead
E. Stanley O’Neal
Estate of Beatrice P. K. Palestin
The Pediatric Cancer Foundation
The Perelman Family Foundation
Trust of Elizabeth L. Perkins
Perry Capital LLC
Margot Rosenberg Pulitzer Foundation
John Bradbury Reed
Trust of Irene Dorothy Reel
Estate of Agnes Rezler
Estate of Edith Roberts
The Arthur Ross Foundation, Inc.
Trust of Edward G. Ryder
Dr. and Mrs. Nathan E. Saint-Amand
Estate of Alana M. Schuster
The Beatrice & Samuel A. Seaver Foundation
The Seraph Foundation
Dr. David E. and Beth Kobliny Shaw
Trust of William and Isabelle Sherlock
Mr. and Mrs. H. Virgil Sherrill
Mr. and Mrs. Stephen C. Sherrill
M. Steven and S. David Silberman
Trust of Barbara K. Snader
The Santag Foundation
Spin4Survival
Sportsmen for Charity
The John R. and Inge P. Stafford Foundation
Estate of Helen E. Steadman
The Mel Stottlemeyer Myeloma Foundation
Trust of James Strobridge
The Sussexean Family Fund
The Michael Sweig Foundation
Barbara Davies Troisi Foundation
Tudor Investment Corporation
Daniel P. and Grace I. Tully Foundation
Turner Construction Company
United Way of Tri-State
Trust of Ward M. Vanderpool Variety – The Children’s Charity
Estate of Christine Villano
The Lucy R. Waletzky Fund
Trust of Thomas J. Watson, Jr.
Trust of Reamer W. Wigle
Mr. and Mrs. Sam Wilderman
The Meryl and Charles Witmer Charitable Foundation
Trust of Richard A. Yudkin
Estate of Anna M. Zavatt
Zev’s Fund Inc.

$250,000 — $499,999

Trust of George Aaron
Accelerate Brain Cancer Cure (ABC2) Foundation
Estate of John D. Adams, Jr.
The Rita Allen Foundation
The Alliance Against ASPS Foundation
Trust of Eileen Alpert
Mr. and Mrs. John Angelo
Anonymous
Estate of Anita S. Appel
Mr. and Mrs. Frank W. Appleton, Jr.
Joyce Ashley
Estate of Rose Ashton-Irvine
Estate of William C. Bahn, Jr.
The Banbury Fund
Trust of Marcia Batten
Richard L. Beattie
Estate of Ethel A. Bell
The Bie Family Foundation
The Lisa E. Biotto Foundation
Nancy Shevel Blakeman
The Nancy and Robert S. Blank Foundation
The Blue Dot Foundation
The Louis L. Borick Foundation
The Albert C. Bostwick Foundation
Estate of Adele Bozio
Trust of Nancy J. Bradford
Trust of Alice M. Branch
The Braver Foundation
Mr. and Mrs. Peter Bren
Trust of Dorothy Fielder Brown
Estate of Madalyn B. Bryant
The Bugas Fund
Hilary and Joseph A. Califano, Jr.
Cancer Research Institute
Cancer Support Services, Inc.
Estate of Georgia M. Catrini
The James and Patricia Cayne Charitable Trust
Trust of Ruth C. Celarek
Estate of Burdette G. Chamberlin
Joan Chorney
CIBC World Markets Corporation
Estate of Dorothy L. Cobb
Trust of Joan F. Cobb
Mr. and Mrs. John K. Colgate, Jr.
The Simon and Eve Colin Foundation
Estate of Robert I. Conley
Estate of Lillian Copperman
Carlos Cordeiro
Estate of Leonard Cossack
Chandler Cox Foundation
Estate of Mary O. Craft
Estate of Edna W. Curl
Mr. and Mrs. Marvin H. Davidson
Trust of Richard L. Davies

Estate of Frederick W. Davis
Trust of Marion E. Dean
The Thompson Dean Family Foundation
Trust of Carolyn B. Denney
The Dickson Foundation
The DiMenna Foundation, Inc.
Elizabeth K. Dollard Charitable Trust
Trust of James Douglas
The Walter S. and Lucienne B. Driskill Foundation
Estate of Louis Duenweg
Mr. and Mrs. Barclay Ehler
The Mizzi and Warren Eisenberg Foundation
Eli Lilly & Co.
Rita H. Schaefer Elliott
The Emerald Foundation
Trust of June K. Evans
Lord Evans of Watford
Trust of Sarah W. Ewing
Mr. and Mrs. Barton Faber
Estate of Giuliana Fantini
The Feinstein Family Foundation
The Grace J. Fipperger Foundation, Inc.
The Jodi Spiegel Fisher Cancer Foundation
Aaron I. Fleischman Foundation
The Floren Family Foundation
Fondazione Italiana Leonardo Gianbrone
For the Love of Life
The Terry Fox Run for Cancer Research
The Evan Frankel Foundation
The Edna R. Fredel Charitable Lead Annuity Trust
The Fribourg Foundation
Jeannette R. Fulham
Estate of Regina M. Gallichio
Estate of Norman D. Galloway
Trust of Esther B. Garsney
Estate of Mildred B. Gehrke
Joe & Ellen Gellert
The Aaron and Betty Gilman Family Foundation
The Albert and Pearl Ginsberg Foundation
The Glenstone Foundation
Mr. and Mrs. Robert S. Goldberg Granary Associates
Mr. and Mrs. Alan I. Greene
Mr. and Mrs. Martin D. Gross
Peter M. Guggenheimer
Robert C. Halboth
Mrs. Melville W. Hall
Mr. and Mrs. Stephen L. Hammerman
Richard Hanlon
Susanne and Shelley Harrison

Trust of Abraham Hases
Estate of Irma Hayes
The Catie Hoch Foundation
Mr. and Mrs. D. Gregory Horrigan
Estate of Karen L. Hudson
The Patricia M. Hynes & Roy L. Reardon Foundation
IBM Corporation
IBM International Foundation
Bruce H. Jacobs
Janssen Pharmaceutical Products LP
Estate of Mira Jelin
The Jewish Communal Fund
Joan’s Legacy: The Joan Scarangello Foundation to Conquer Lung Cancer
The Robert Wood Johnson Foundation
Estate of Al Jolson
Estate of Robert L. Jones
Mr. and Mrs. Robert B. Kay
Estate of Helen Keena
Trust of Fenton O. Keister
John R. Kennedy
The Fred W. Kramer Charitable Trust
Estate of Harriette H. Kussin
Sidney Lacher
Mr. and Mrs. Joseph M. La Motta
Estate of Harriet L. Lambert
Trust of Charles T. Larus
Vivian F. Laube
Lavelle Fund for the Blind, Inc.
Betty Reid Lawson
Trust of Joseph Lebednik
Trust of Leona Levy
Pauline H. Lin
Estate of Marion J. Looser
Mr. and Mrs. Edward Lundy
Earle I. Mack Foundation
Julian Malkiel
Manhasset Women’s Coalition Against Breast Cancer
The Lois H. Mann Charitable Foundation
Estate of Albert Manning
Estate of Marvin Margolies
Estate of Edith Lippard Martens
Estate of Elizabeth Martin
Trust of Richard and Betty Martin
Estate of Ann L. Martinez
The Lucille and Paul Maslin Foundation
Trust of Cecelia Matarazzo
Estate of Harry H. Maus
MBNA America Bank
The MBNA Education Foundation
Donald J. McCarragh
The Michael W. McCarthy Foundation
Estate of Charles McGreevy
Estate of Alan McMaster
The Merck Company Foundation
The Ambrose Monell Foundation
Morgan Stanley
Mr. and Mrs. Charles H. Mott
Trust of Edmund L. Murray
Raymond Neag
Muriel Neumann
The New York Yankees Foundation
Occidental Petroleum Corporation
Grace Oughton Cancer Foundation
Elsa U. Pardee Foundation
The Perkin Fund
Estate of Ann Perkins
Estate of Claude E. Petruzzi
Pfizer Inc.
Estate of Lucie Picard
Josephine K. Poling
Estate of Elizabeth Polotaye
Trust of Helen M. Price
Project A.L.S.
Prudential Financial, Inc.
Purdue Pharma LP
Leslie C. Quick and Regina A. Quick Charitable Trust
Trust of Anne Ressner
Trust of Lillian Robbins
Estate of Sandra Sheppard Rodgers
Estate of Nathan Rothstein
Estate of Wilhelmina T. Rouget
The Selma and Lawrence Ruben Foundation
Mrs. Orhan I. Sadik-Khan
Mr. and Mrs. Ricky Sandler
Trust of Erika Saphier
Estate of Anabel M. Scarborough
Trust of erika Saphier
The Seth Sprague Educational and Charitable Foundation
The Robert Steel Foundation for Pediatric Cancer Research
Estate of Sonia Stolin-Moresco
The Daniel P. Sullivan Clinical Fellowship Fund
Frank N. Tedesco
Estate of Ida Tepper
Trust of Annette M. Terdina
The Craig D. Tifford Foundation, Inc.
United Hospital Fund of New York
United Leukemia Fund Inc.
United Way of New York City
Estate of Eleanor B. Vogel
The Wissley Family Foundation
Estate of Ingeborg K. Watson
The Scott Weingard Memorial Fund
Effie Wells-Lonning
Trust of Ida Wharton
John C. Whitehead
Estate of Ruth Whitfield
Mr. and Mrs. Frank C. Whittelsey III
Mr. and Mrs. Sam Wilderman
Trust of Vincent J. Zappolo
Mr. Ronald Zung

$100,000 — $249,999

The Louis & Anne Abrons Foundation, Inc.
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
The Louis & Bessie Adler Foundation
The Francis X. Ahearn, Sr. Foundation
Daniel G. Alexander
Robert and Elaine Allen
Mr. and Mrs. Robert I. Alpern
The Amaturo Foundation, Inc.
The American Ireland Fund
The Ametek Foundation, Inc.
Asgen, Inc.
Estate of Maurice Amzalak
Dorothy A. Anderson
Mr. and Mrs. Harold F. Anderson
Anonymous
Mr. and Mrs. Rand Araskog
Mr. and Mrs. William J. Armfield IV
Kym S. Arnone
Mary Kay Ash Charitable Foundation
Trust of Maureen E. Bacchi
Dr. Joseph J. Bailey
Elliot A. Baines
The Baird Family Fund
Mr. and Mrs. Robert L. Barbanell
Estate of James R. Barber
Estate of Kaethe F. Barry
Betsy L. Battle
Estate of Thelma Beatty
Trust of Gertrude E. Beck
Rosalie Becker
The Arnold and Mabel Beckman Foundation
Estate of Charles R. Beechler
Estate of Robert D. Bennett
Corinne Bereuzk and Michael Stieber
Tony P. Beranbach
The Bill Bernbach Foundation
Robert Berne
Mr. and Mrs. Louis Bernstein
Jill & Darius Bickoff Foundation
Estate of Margaret L. Bingman
Biomet
Jamie Nicholls & Fran Biondi Charitable Trust
Alexander Blass
Mr. and Mrs. James A. Block
Estate of Vivian K. Blonder
The Walter & Adi Blum Foundation, Inc.
Trust of Eli Blumenfeld
Harold and Adele Blumenkrantz
Estate of Simon P. Blustone
Bruce Bocina
Estate of Marti A. Boden
Albert and Betty Bodian
The Bondi Foundation
Estate of Marjorie R. Boselly
Alan F. Boove
William R. Boyle
Estate of Mary C. Brabson
Estate of Elsie L. Bradford
Brahman Capital
Milton Brenner
Estate of Mae Bridewell
Trust of Marie H. Brock
Estate of Edna Brodie
Randall Brooks
Carl and Nicky Brown
Catherine D. Brown
Trust of Ruth Ann Brown
Estate of Vernon Brunelle
Elizabeth Bucher
Janna Bullock
Trust of Florence Bunn
Mr. and Mrs. Franz H. Bunda
Mr. and Mrs. Edwin M. Burke
Estate of Louise V. Burnett
Estate of Lillian A. Byman
Mr. and Mrs. Bruce L. Calhoun
Leah Rush Cann
Estate of Edward A. Cantor
The Paul Robert Carey Foundation
Mr. and Mrs. Kenneth Carmel
Estate of William K. Carson
Colon B. Carter
Trust of Winifred T. Carter
Joan (Perkowski) Cashin Foundation
Casual Male Corp.
The Cayuga Foundation
Estate of Charlotte A. Celian
Trust of George F. Chagnot
Margaret Anne Chappell
Estate of Camille Chericone
Child Neurology Foundation
The Children’s Brain Tumor Foundation
Mr. and Mrs. Allen Chipman
Florece Chu, M.D.
Estate of Lyman W. Clardy
The Clark Foundation
Cleveland Clinic Health System
Clarence L. Coleman Jr. and Lillian S. Coleman Foundation
Estate of Gertrude T. Coles
Arthur R. Collins
Estate of Lila V. Collins
Terry S. Collins
Consolidated Edison Company of New York
Dudley P. Cook
Mr. and Mrs. Errol M. Cook
Mrs. William B. Cook
E. Gerald Cooper
G.R. Couch
Gloria S. Fine
First Quality Enterprises, Inc.
Estate of James K. Fisher
Jeanne Donovan Fisher
Estate of William and Frederica Fissell
Trust of Loretta B. Fitzgerald
Trust of William Forbes
Mr. Richard N. Foster
Claire and Meyer W. Frank and Leamn Frank
Charitable Foundation
Trust of Irene R. Frank
Helen Frankenthaler Foundation
Trust of Jill and Jayne Franklin
Mr. and Mrs. Frank O. Fredericks
Gloria Freed
Frey Family Foundation, Inc.
Knawm Friedman
Richard M. Furlaud
G & P Foundation for Cancer Research
Mr. and Mrs. Thomas J. Gahan
Trust of Ralph W. Gaines
Estate of Anne Gallagher
Trust of William G. Genner, Sr.
Genzyme
Panayotis Gerolymatos
Estate of Theresa A. Girharlinghelo
Mr. and Mrs. William H. Girvan
GIST Cancer Research Fund
The Glades Foundation
Mr. and Mrs. Eugene J. Glaser
Glennwood Management Corporation
Trust of Glenn R. Goble
Trust of Marc S. Goldberg
The Goldhirsh Foundation
Estate of Elizabeth B. Golding
The Joyce & Irving Goldman Family Foundation
Goldman Sachs & Company
The Barbara L. Goldsmith Foundation
The Alfred G. and Hope P. Goldstein Foundation
Susan Wallack Goldstein
Trust of Manuel and Anne Goodman
The Gordon Family Foundation, Inc.
Mr. and Mrs. Sheldon M. Gordon
Arthur A. Gosnell
Marietta A. Goulardris
Estate of Richard P. Gould
Felice M. Grad
Graff Diamonds
Grantham Mayo Van Otterloo & Co.
The Grateful Foundation, Inc.
Brigadier General and Mrs. William S. Greenberg
Estate of Edythe Grifflinger
Trust of Vernon H. Grigg
Virginia and Howard Groombridge
Estate of J. Stanley Gross
Trust of Lambert J. Gross
Audrey and Martin Gross Foundation
Marilyn B. Gula Mountains of Hope Foundation
Trust of Elizabeth Guon
Gloria E. Gurney
Estate of Gloria E. Gurney
Gurney Foundation
The Hagedorn Fund
Estate of Elizabeth W. Hall
Estate of Mazie J. Hall
Estate of Helen Sue Hameetman
Trust of Florence M. Hammer
Milton and Miriam Handler Foundation
Estate of Marion K. Hardwicke
Dorothy Harlow
Glady's and Roland Harriman Foundation
Mary Jane Harrington
Perry Harten
Laura Hartenbaum
Breast Cancer Foundation
Morris A. Hazan Family Foundation
Trust of Loni G. Hearn
Hecht & Company Philanthropic Foundation
Trust of Shirley S. Heilman
The Heimbold Foundation
Mr. and Mrs. John Hennessy
The Maxine R. and Richard L. Henry Trust
Robert Hensel, Jr.
Carolina Herrera, Ltd.
Trust of Leon Hershaft
Trust of Marie Hesselbach
Heyman-Merrin Foundation
Hillenbrand Family Foundation
Trust of Myfanwy Hinkle
Estate of Vladimir Hladik
The Y.C. Ho/Helen and Michael Chang Foundation
Estate of Edward B. Hodge
Hoffman-La Roche Inc.
Estate of Marion Hoffman
Estate of Ruth M. Hoffman
Trust of Steward B. Hoffman, Sr.
Deborah H. and Sigmar K. Hoffman
Mrs. Carolyn T. Holden
L. Evelyn Holdren
Estate of Herman L. Hoops
Alfred Samson Hou
Robert Howard Family Foundation
Evelyn Huber
The Howard Hughes Medical Institute
Nancy Hughes
Carol Hunter
Edith M. Hunter
James B. Hunter
Syde Hurdus Foundation, Inc.
Mr. and Mrs. David W. Ichel
Estate of Priscilla T. Iden
Inamed Corporation
The Interpublic Group of Companies
Irish Society of Medical Oncology
It Figures LLC
Trust of Clyde H. Jacobs
Harry A. Jacobs, Jr.
Mr. and Mrs. Stanley R. Jaffe
Trust of Ann E. Jennings
The JMB Hope Foundation
The Samuel C. Johnson Trust
Max Kade Foundation, Inc.
The Kahn Charitable Foundation
Trust of Frank J. Kahn
Jane Kalmus
Harry P. Kamen Family Foundation
Estate of Eleanor Kane
Estate of Bernard Kantor
Steve and Meghan Kanzer
Marie H. Karger
The Karma Foundation
Trust of Jerry Katz
Edward M. Kaufman
Trust of John Kaufmann, Jr.
Mr. and Mrs. Robert M. Kavner
Mr. and Mrs. Brian G. Kelly
Estate of Ruth C. Kelly
Mrs. Ann Kelman and the late Dr. Charles D. Kelman
Estate of Herman Kerner
J. Kevin Kenny
John A. Kent
The Glenn D. Kesselhaut Children’s Joy Fund
Mr. and Mrs. Peter A. Kessler
The Kettering Family Foundation
Doris and Floyd Kimble Foundation
The King Family Charitable Lead Trust
Mr. James W. Kinnear II
Patricia A. Kirby
Robert D. Klemme
The Esther and Joseph Klingenstein Fund
Trust of Estelle Knapp
Fernand Koch
Estate of Gale K. Kokubu
Emanuel Kondoleon
The Koppelman Family Foundation
The Gwen L. Kosinski Foundation
Mr. and Mrs. Marvin H. Koslow
Robert A. Kotick
Mr. and Mrs. Jerome I. Kroll
Cheryl Gordon Krongard
Mr. and Mrs. Jeffrey W. Kronthal
Mr. and Mrs. William L. Kronthal
Trust of Grace E. Kruse
The Lakeside Foundation
Estate of Schubert L. Lamb
Estate of Marvadene B. LaMonica
The Edward & Kinga Lampert Foundation
Emma Landau
Mr. and Mrs. Barry Lang
Estate of Annie Langen
Anne Lanigan
J. Clair and Pamela Lanning
Trust of Edwin S. Lee, Jr.
Nicole Feller Lee
Lehman Brothers Inc.
Karen and James Lehrburger
Mr. and Mrs. Lewis E. Lehman
Estate of Donald LeRoy
The Leukemia & Lymphoma Society
Mr. and Mrs. Allan L. Levey
Estate of Dina Levinsky
Estate of Erna T. Lewine
The Anne Boyd Lichtenstein Foundation
Trust of Wilhelmina L. Lipert
Lisa’s Heart Kids’ Cancer Research Fund
The Harold I. & Faye B. Liss Foundation
Mr. and Mrs. Martin Liss
Julia Little
Live4Life Foundation
Demarest Lloyd, Jr. Foundation
Harry J. Lloyd Charitable Trust
Estate of Anthony Lopez
Milton Lowenstein
James J. and Marianne B. Lowrey
The Lucerne Foundation
Lung Cancer Research Foundation
Lymphoma Research Foundation
Trust of John F. Lynch
Estate of Kathleen E. Lynch
Estate of Charles S. Lyons
Estate of Melvin E. Lyons
The M and N Fund in Community Funds, Inc.
MacDonald-Peterson Foundation
Josiah Macy, Jr. Foundation
Estate of Margaret H. Mairs
The Arthur and Holly Magill Foundation
The Maguy Foundation
Elissa Caterfino Mandel
Estate of Harry Marder
Estate of Ida Mae Margolis
Trust of Clarkson G. Marie
Mr. and Mrs. Bernard Marin
Edward J. Marino
MRS. JOHN L. MARION
SUSAN AND MORRIS MARK
JEROME S. AND MARIA MARKOWITZ
Estate of Benjamin Marmer
The Marmot Foundation
The Christina & Paul Martin Foundation
Martin Elk League for Cancer Research
Dorothy Marx
Trust of Anthony Masard
Estate of Rita B. Masse
The Hale Matthews Foundation
Trust of Walter J. Matthews
The Matt’s Promise Foundation
Maverick Capital Charities
The Mayday Fund
Maynard Childhood Cancer Foundation
The Helen & William Mazer Foundation
Mr. and Mrs. Louis V. Mazella
Mary Jane McCarthy
Mr. and Mrs. Thomas McCullough
McDonald Financial Group
Ralph McDonough
The Dextra Baldwin McConagle Foundation
Estate of Geoffrey McLoughlin
Mr. and Mrs. David B. McQueary
Estate of Dorris M. Mendelsohn
Estate of Irving M. Mendelson
Estate of Lorraine Mensing
The Reuven Merker Charitable Foundation, Inc.
Estate of Amy Joan Meskin
Mr. Robert A. Metzler
Estate of Abby E. Meyer
Trust of Russell A. Meyer
Sir Peter and Lady Michael Foundation
Mrs. Sidney Michael
Trust of William M. Michaelson
Trust of Florence B. Mickels
The Milbank Foundation for Rehabilitation
Elaine P. Miles
Eleanor F. Miley
Carolyn Rosen Miller
Family Foundation
Mr. and Mrs. Matthew Miller
Mrs. Minot K. Mililiken
Mr. and Mrs. James W. Milton
The Mike and Steve Foundation
Estate of Catherine Mohan
Trust of Celestine Elizabeth Moloney
Estate of William Monaghan
Arthur R. Montgomery
Daniel S. Goldman and Anne K. Montminy
John and Hee-Jung Moon
Estate of Pauline Moor
Mr. and Mrs. Charles V. Moore
Estate of Percy W. Moore
Estate of Barbara B. Morgan
Manuel and Mercedes Mosteiro
Virginia M. Mueller
Ernest Muth
Edith L. Nathanson
The National Genetics Foundation, Inc.
Estate of Leslie A. Nelkin
New York City District Council of Carpenters Relief and Charity Fund
New York Workers’ Compensation Bar Association
Gerald L. Nichols and Jacqueline W. Nichols Foundation
James G. Niven
NYS Fraternal Order of Police Foundation
The Michael A. O’Bannon Foundation
Ernestine A. O’Connell
Trust of Emily C. O’Grady
Estate of Grace O’Hare
Oki Data Americas, Inc.
The Okonite Company
Optiscan
Otis Elevator Company
The William & Jane Overman Foundation
Parfums de Coeur Ltd.
The Parnassus Foundation
Trust of Edith Pattison
Estate of Herman L. Paul, Jr.
Mr. and Mrs. Kenneth Pearlman
Pediatric Brain Tumor Foundation
Trust of James A. Pemerton
PepsiCo Foundation, Inc.
Pershing Square Foundation
Estate of Frederick D. Petrie
The Pew Charitable Trusts
Samantha and Ernst Pfenninger
Trust of Peter H. Pfugk
Mr. Alessandro Pinto
Jean D. Pitcher
Estate of Beatrice Pockrass
Polo Ralph Lauren Corporation
Chere Henderson and David Poppe
Janis Z. Porch
Trust of Ann C. Porterfield
Estate of Edna G. Potter
Rita Price
Estate of Seymour Price
Ardys M. and Harold I. Proctor
The Proctor & Gamble Company
The William H. Prusoff Foundation
Mrs. Jenice Pulver
Richard I. Purnell Fund
Estate of Richard I. Purnell
Roselyn Flum Radcliffe
Muriel Rains
John H. Rassweiler
Abigail T. Reardon
Estate of Phyllis E. Redmerski
Elenore Reed
Estate of Martha Cuneo Reed
Samuel P. Reed
The Beatrice Renfield Foundation
Estate of Roland S. Rhode
The Rice Family Foundation
Martin Rich
Anne S. Richardson Fund
Harry Rinehimer
Estate of Elizabeth M. Ringo
Trust of Victoria Rinius
The Fannie E. Rippel Foundation
The Ritter Family Foundation
Abigail Rittmeyer
The Andréa Rizzo Dance Therapy Fund
The RMF Family Fund, Inc.
Mr. and Mrs. Stephen Robert
Estate of Floyd B. Roberts
Vivien Rock
Rodale, Inc.
Mr. and Mrs. Alexander J. Roepers
Estate of Maria Rolfe
Vittorina Rolfo
Sheldon Rose
Estate of Sylvia Rosenberg
Trust of Ilsa Rosenblum
Trust of Evelyn Rosenberg
Estate of Sylvia Ross
Estate of Eva L. Rothberg
Mr. and Mrs. Eric A. Rothfeld
Denise Rover
David Mark Rubenstein
Mr. and Mrs. Mitchell E. Rudin
Estate of Maria Stella Ruggirello
Estate of Eileen B. Ruthrauff
Janet Lee Kadesky Ruttenberg
The Raymond & Beverly Sackler Foundation
Mrs. Edmond J. Safra
The Sabel Foundation
Mr. and Mrs. Herbert E. Saks
Mr. and Mrs. Eugene L. Salem
Mr. and Mrs. William R. Salomon
Trust of Sidney Samuels
Henry Sanborn
Mrs. Barbara Santangelo
The Saw Island Foundation
Trust of Paul C. Sawyer
Estate of Ida M. Scagliarini
Scalamandre Silks
Dida and Oscar S. Schafer
Peter L. Schaffer
The Milton Schamach Foundation, Inc.
Estate of Richard Scharff
Estate of Josephine L. Schiff
Estate of Billie Schneider
Trust of Jennie C. Schneider
The Schneider-Kaufmann Foundation, Inc.
Mrs. Silvia A. Schnur
Estate of Harold B. Schwartz
The Washington Post Company
Mr. and Mrs. Bruce Wasserstein
Jesse and Doris Weaver
Mr. and Mrs. Bradford G. Weekes II
Mrs. John L. Weinberg
Mr. and Mrs. Michael Weisberg
Estate of Gertrude Weiss
John A. Weissenbach and
Ann Southworth
Trust of Gertrude Wellisch
The Nina W. Werblow
Charitable Trust
Mr. and Mrs. Harold S. Wertheimer
Mrs. Elizabeth G. Weymouth
Whitehall Foundation, Inc.
Estate of Frank A. Widenski
The Jesse R. Wike Charitable Trust
Williams Trading LLC
Trust of Helen A. Wilson
Estate of Gordon Wootton
Alfred D. Youngwood
The Patricia J. and Edward W. Zeh
Charitable Foundation
The Zickler Family Foundation
The Isaac Ziegler Charitable Trust
Stanley Shalom Zielony Foundation
Ziff Brothers Investment, LLC
Martha E. Zimmer
Larry and Anne Zimmerman
Mr. and Mrs. Nicholas B. Zoullas
Estate of Rosalind Schwartzbach
Trust of Paul J. Schwarz
Mrs. Arline Schwarman
Trust of Robert E. Schwenk
Mr. and Mrs. John W. Scully
Estate of Jewel C. Seab
The Jean & Charles Segal
Foundation
The Select Equity Group Foundation
The Nina and Ivan Selin
Family Foundation
R.B. Sellers Foundation
The Jacqueline Seroussi
Memorial Foundation
Seventh District Association, Inc.
L.J. Sevin
Harold Shames
Estate of Reuben Shane
The Shanken Family Foundation
The Sharma Foundation
Estate of Bernice Baruch Shawl
William R. Sheldon
Estate of Alice Sherwin
Estate of Leo A. Shifrin, MD
Mr. and Mrs. Stanley B. Shopkorn
Mr. and Mrs. William Shulevitz
Mr. and Mrs. Steven J. Sidewater
The Muriel F. Siebert Foundation
Estate of Ruth Siegmann
Mary Siekert
The Grace, George, and Judith
Silverburgh Foundation
Evelyn R. Simmers Charitable Trust
The Seymour Simon Charitable Trust
Marilyn M. Simpson Charitable Trust
Simpson Thacher & Bartlett
Estate of Shirley Singer
Estate of Madeline Sisak
Estate of Alvin F. Sloan
Suse Smetana
Estate of Woodrow Q. Smith
Catherine M. Smolich
The Beatrice Snyder Foundation
Mr. and Mrs. Brian Snyder
Trust of Robert Solnick
Professor and Mrs. C. Alan Soons
Soros Fund Charitable Foundation
Sotheby’s
The Roy M. Speer Foundation
Regina W. Spence
Estate of Agnes Spillner
The Seth Sprague Educational and
Charitable Foundation
The St. Giles Foundation
Estate of Dennis Stein
The Fred & Sharon Stein Foundation
The Ernest E. Stempel Foundation
Mr. and Mrs. Howard Stern
Estate of Irene Stern
Winona H. Stevens
Trust of Charles M. Stevenson
The Guy M. Stewart Cancer Fund
J. McClain Stewart
Estate of Rebecca Stohl
Estate of Clair B. Stough
Estate of Herta Strauss
Mr. and Mrs. Paul A. Street
Geraldine Stutz Trust Inc.
Trust of Mary R. Suchanski
Mr. and Mrs. Robert J. Sullivan
Dorothy D. Taggart Trust
J.T. Tai & Co. Foundation, Inc.
Ping Y. Tai Foundation
Trust of Andrew Taras
Edward Tarby
Estate of Ruth N. Taub
Estate of Florence G. Taylor
Estate of Gertrude S. Taylor
Telethon Italy – US Foundation
Estate of Walter G. Teredewow
Estate of Stella F. Thater
Estate of Robert P. Thorne
Trust of Vernon Thompson
Mr. and Mrs. Carl W. Timpson, Jr.
Estate of Margaret R. Tomas
Estate of Milton Topolsky
Estate of John J. Tormey
The Tortuga Foundation
Trust of Angelina Ann Tovar
Jill Tracey
Trust of Helen A. Trahan
Trust of Dorothy B. Traufeld
The Robert Mize & Isa White
Trimble Family Foundation
The W. James & Jane K. Truettner
Foundation
Thomas N. Tryforos
Estate of Ina Tuckman
R. Read Tull
Lucien L. and Shirley Turk
The Tyler Foundation
Ahavas Tzedek Foundation
The Lucy & Eleanor S. Upton
Charitable Foundation
The Valley Foundation
Valley of the Sun United Way
Vanguard Charitable
Endowment Fund
The Varnum Derose Trust
The Vasey Foundation
The Victoria’s Smile Foundation
The Family of Maria Elena Villanueva
Estate of Dorothy Voelker
Trust of Anna L. Vogel
Estate of Gertrude Vogel
Trust of Beverly Wachtel
The Paul E. and Mary Wagner Trust
Estate of Lillie M. Waldon
Mr. and Mrs. Paul D. Walsh
Estate of Frances M. Wanek
Warren/Soden/Hopkins
Family Foundation
Trust of Gertrude Wellisch
The Nina W. Werblow
Charitable Trust
Mr. and Mrs. Harold S. Wertheimer
Mrs. Elizabeth G. Weymouth
Whitehall Foundation, Inc.
Estate of Frank A. Widenski
The Jesse R. Wike Charitable Trust
Williams Trading LLC
Trust of Helen A. Wilson
Estate of Gordon Wootton
Alfred D. Youngwood
The Patricia J. and Edward W. Zeh
Charitable Foundation
The Zickler Family Foundation
The Isaac Ziegler Charitable Trust
Stanley Shalom Zielony Foundation
Ziff Brothers Investment, LLC
Martha E. Zimmer
Larry and Anne Zimmerman
Mr. and Mrs. Nicholas B. Zoullas
### ADMINISTRATIVE BOARD

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Mrs. Peter D. Jones</td>
</tr>
<tr>
<td>Vice President</td>
<td>Mrs. Thomas V. Leeds</td>
</tr>
<tr>
<td>Vice President</td>
<td>Mrs. Brian A. McCarthy</td>
</tr>
<tr>
<td>Vice President</td>
<td>Mrs. Brian Snyder</td>
</tr>
<tr>
<td>Treasurer</td>
<td>Mrs. John B. Glass, Jr.</td>
</tr>
<tr>
<td>Secretary</td>
<td>Alexia Hamm Ryan</td>
</tr>
<tr>
<td>Assistant Treasurer</td>
<td>Mrs. Scott C. Johnston</td>
</tr>
<tr>
<td>Assistant Secretary</td>
<td>Mrs. Lars Forsberg</td>
</tr>
<tr>
<td>Vice President</td>
<td>Mrs. Kenneth Joseph</td>
</tr>
<tr>
<td>Vice President</td>
<td>Mrs. Richard S. LeFrak</td>
</tr>
<tr>
<td>Treasurer</td>
<td>Jeanette W. Loeb</td>
</tr>
<tr>
<td>Secretary</td>
<td>Mrs. Roman Martinez IV</td>
</tr>
<tr>
<td>Treasurer</td>
<td>Mrs. S. Christopher Meigher III</td>
</tr>
<tr>
<td>Secretary</td>
<td>Mrs. Richard A. Miller</td>
</tr>
<tr>
<td>Treasurer</td>
<td>Mrs. George F. Moss</td>
</tr>
<tr>
<td>Secretary</td>
<td>Mrs. George K. Moss</td>
</tr>
<tr>
<td>Treasurer</td>
<td>Mrs. Richard T. Perkin</td>
</tr>
<tr>
<td>Secretary</td>
<td>Debra L. Pipines</td>
</tr>
<tr>
<td>Treasurer</td>
<td>Mrs. Samuel F. Pryer IV</td>
</tr>
<tr>
<td>Secretary</td>
<td>Mrs. Bambi Putnam</td>
</tr>
<tr>
<td>Treasurer</td>
<td>Dr. Annette U. Rickel</td>
</tr>
</tbody>
</table>

### SUSTAINING BOARD

<table>
<thead>
<tr>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mrs. Andres Bausili</td>
</tr>
<tr>
<td>Mrs. William C. Beutel</td>
</tr>
<tr>
<td>Mrs. Kevin A. Bousquette</td>
</tr>
<tr>
<td>Mrs. D. Wayne Calloway</td>
</tr>
<tr>
<td>Nancy Mulholland Conroy</td>
</tr>
<tr>
<td>Mrs. James F. Curtis III</td>
</tr>
<tr>
<td>Mrs. James H. Dean</td>
</tr>
<tr>
<td>Mr. Thompson Dean</td>
</tr>
<tr>
<td>Antonia Paepcke DuBrul</td>
</tr>
<tr>
<td>Mrs. Thomas J. Fahey, Jr.</td>
</tr>
<tr>
<td>Mrs. Lee M. Gammill, Jr.</td>
</tr>
<tr>
<td>Mrs. Peter K. Hills</td>
</tr>
<tr>
<td>Mrs. John S. Hilson</td>
</tr>
<tr>
<td>Mrs. Ann F. Jeffery</td>
</tr>
<tr>
<td>Julie Kammerer</td>
</tr>
<tr>
<td>Suzanne McDonnell Long</td>
</tr>
<tr>
<td>Mrs. Carmel Malkin</td>
</tr>
<tr>
<td>Mrs. Timothy Malloy</td>
</tr>
<tr>
<td>Mrs. Minot K. Milliken</td>
</tr>
<tr>
<td>Mrs. Charles D. Peebler, Jr.</td>
</tr>
<tr>
<td>Mrs. Francois de Saint Phalle</td>
</tr>
<tr>
<td>Mrs. Roy R. Plum</td>
</tr>
<tr>
<td>Mrs. Howard L. Ross</td>
</tr>
<tr>
<td>Evelyn Angevine Silla</td>
</tr>
</tbody>
</table>

### ADVISORY COUNCIL

<table>
<thead>
<tr>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mrs. Rand V. Araskog</td>
</tr>
<tr>
<td>Mrs. Charles A. Dana, Jr.</td>
</tr>
<tr>
<td>Mrs. John R. Drexel III</td>
</tr>
<tr>
<td>Mrs. Catherine Marron</td>
</tr>
<tr>
<td>Mrs. Milton Petrie</td>
</tr>
<tr>
<td>Linda Gosden Robinson</td>
</tr>
<tr>
<td>Mrs. H. Virgil Sherrill</td>
</tr>
</tbody>
</table>

### PAST PRESIDENTS

<table>
<thead>
<tr>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mrs. Coleman P. Burke</td>
</tr>
<tr>
<td>Mrs. Edwin M. Burke</td>
</tr>
<tr>
<td>Mrs. William M. Carson</td>
</tr>
<tr>
<td>Mrs. Walter B. Delafield</td>
</tr>
<tr>
<td>Mrs. Charles H. Dyson</td>
</tr>
<tr>
<td>Mrs. Bruce A. Gimbel</td>
</tr>
<tr>
<td>Mrs. William O. Harbach</td>
</tr>
<tr>
<td>Alison Barr Howard</td>
</tr>
<tr>
<td>Mrs. Kerry King</td>
</tr>
<tr>
<td>Mrs. Arie L. Kopelman</td>
</tr>
<tr>
<td>Mrs. Derek L. Limbocker</td>
</tr>
<tr>
<td>Jean Remmel Little</td>
</tr>
<tr>
<td>Mrs. M. Anthony May</td>
</tr>
<tr>
<td>Mrs. Jay H. McDowell</td>
</tr>
<tr>
<td>Mrs. Frank L. Metz, Jr.</td>
</tr>
<tr>
<td>Mrs. Bijan Safai</td>
</tr>
</tbody>
</table>

### FOUNDER

<table>
<thead>
<tr>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mrs. Edward C. Delafield</td>
</tr>
</tbody>
</table>

### EXECUTIVE DIRECTOR

<table>
<thead>
<tr>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maryanne Greenfield</td>
</tr>
</tbody>
</table>
Founded in 1946, The Society of MSKCC is a volunteer organization that has provided more than six decades of service to ensure the well-being and comfort of patients, raise funds for cancer research and treatment, and educate the public about cancer. Society members actively participate on 22 committees that raise money for The Society’s programs and work closely with Memorial Hospital staff and leadership to implement them.

The Society’s Patient Environment Program, or PEP, works with MSKCC employees who have demonstrated a keen understanding of patients’ needs to make improvements to the hospital setting. Each year, PEP funds a number of initiatives proposed by MSKCC employees designed to benefit patients. This year, projects that received support from PEP included new chairs for ambulatory care patients, blanket warmers for the bone marrow infusion suite, a DVD library for intensive care unit patients and their families, and an acupressure course for nurses to train them to help alleviate pain and manage other symptoms that a patient may experience.

The Social Services Committee of The Society of MSKCC works in partnership with the Department of Social Work to offer financial assistance to patients and their families. The funds are distributed by social workers based on financial need for expenses such as housing, transportation, parking, and patient emergencies. In addition, the Social Services Committee maintains the Patient Emergency Fund, which extends small sums of money for patients in need to help pay for necessities such as medication not covered by insurance, critical daily living expenses including food, and assistance with utilities, rent, and childcare. In 2008, the committee provided 1,115 patients with assistance totaling more than $500,000.

In June, The Society’s Children’s Committee helped bring song, dance, and a revolving disco ball to patients of the Pediatric Day Hospital as part of the annual Pediatric Prom. Members of the Children’s Committee also assisted in the creation of “Promingdale’s” — a boutique set up in the recreation center from which prom-goers could select from an assortment of dresses and tuxedos — and pinned on more than 200 corsages and boutonnieres prior to the festivities.

Now entering its third decade, the Annual Preview Party for The International Fine Art and Antique Dealers Show gave more than 1,000 attendees the opportunity to marvel at works ranging from a blue Tiffany dragonfly lamp to an antique English diamond necklace on view at Manhattan’s Seventh Regiment Armory. A major source of funding since 1989, the October event raised approximately $850,000 for the Center’s programs in patient care, research, and education. The Preview Party was sponsored by Elle Decor and art historian Michel C. Witmer, with additional support from Bacardi USA, Empire Merchants, 1stdibs.com, Bloomberg, and Davidson Kempner Capital Management LLC.

This year The Society debuted a new annual event — the Spring Ball — which was held in the Grand Ballroom of the Plaza Hotel and sponsored by Italian goods retailer Bulgari. The evening culminated in a live auction conducted by James G. Niven, a longtime MSKCC Board member and Vice Chairman of Sotheby’s auction house. The auction contributed more than $600,000 out of the more than $2,875,000 that was raised.

The Associates Committee helps advance MSKCC’s mission by hosting educational meetings, assisting with volunteer efforts at the Center, and organizing fundraising events. This year the Associates Committee hosted several events to fulfill a pledge to raise $1.4 million over four years to endow the Department of Pediatrics’ Clown Care (SM) program. Clown Care is a community-outreach program of the Big Apple Circus that brings specially trained performers to the pediatric inpatient and outpatient units four times a week. In March, the committee’s 17th annual Bunny Hop raised more than $350,000 for Clown Care, and in May the Spring Party, “Safari at Sunset,” raised an additional $336,300.

The Thrift Shop has been a vital part of The Society’s fundraising program for more than 55 years. The shop has been at its current location — Third Avenue between 81st and 82nd Streets — for more than 20 years. Through sales of new and gently used merchandise, including designer and vintage clothing, home furnishings, children’s clothes, books, and artwork, the Thrift Shop provides support for The Society’s patient care, research, and education programs at the Center. In 2008, the shop brought in more than $1.4 million.
1. (From left) Spring Ball Co-Chairman Ashley McDermott, actress Mariska Hargitay, Society President Leslie Jones, Co-Chairman Muffie Potter Aston, singer Natasha Bedingfield, and Co-Chairman Libby Fitzgerald.

2. Joined by a team of Clown Care’s “Doctors of Humorology” at the 17th annual Bunny Hop are Associates Committee Co-Chairs (from left) Elizabeth Fuller, Lisa Ernico, and Christina Addison.

3. An MSKCC pediatric patient has a patriotic good time at the Society-sponsored Pediatric Prom in June.

4. MSKCC President Harold Varmus (left) with Leslie Jones and MSKCC Board member James Niven at the Spring Ball.

5. Present and former Antique Show Preview Party Chairmen gather. (Seated, from left) Karen LeFrak, Barbara Gimbel, Grace Meigher, and Mary Carpenter. (Standing, from left) Alexandra Lind Rose, Lavinia Snyder, Muffie Potter Aston, Joanne de Guardiola, James Niven, Jamee Gregory, Daisy Soros, Leslie Jones, Nicole Limbocker, and Alexia Hamm Ryan.

Those generous friends and benefactors who wish to support the Center as part of the Campaign for Memorial Sloan-Kettering can choose from a range of initiatives designed to benefit the institution at every level — its talented people; its outstanding programs of research, education, and cancer care; and the ongoing demand for the most up-to-date facilities and equipment. The Center especially welcomes donations that help meet its general operating needs, since these provide maximum flexibility in seizing new opportunities as they arise.

All gifts, regardless of size, really do make a difference. Contributions may take a number of forms, including:

- Gifts of cash or cash equivalents, either paid outright in a single installment or as a pledge to be fulfilled over a period of several years. A cash gift may entitle the donor to a charitable deduction of up to 50 percent of adjusted gross income annually, with a carry-over provision of up to five years should the value of the gift exceed 50 percent of the individual donor’s adjusted gross income.

- Gifts of appreciated securities, which offer donors a range of potential benefits such as the avoidance of capital gains taxes when the securities have been held long-term — that is, for more than one year. Such gifts are deductible up to 30 percent of adjusted gross income annually, with a carry-over provision of up to five years should the value of the gift exceed 30 percent of the individual donor’s adjusted gross income.

- Planned gifts, which may help particular donors realize their philanthropic goals more efficiently and comfortably than through outright gifts. These arrangements also allow larger contributions than might otherwise be possible. Planned gifts take a variety of forms, including life income plans such as charitable gift annuities with their relatively generous payout rates and charitable remainder and lead trusts. Individuals who opt to support Memorial Sloan-Kettering through planned gifts may also do so through bequests provided for in their estate plans or by naming the Center as beneficiary of insurance policies or pre-federal income tax qualified plans such as an IRA and certain retirement plans.

- Gifts of real estate and personal property, which may also provide significant tax benefits. In most cases, gifts of real estate allow a donor to claim a tax deduction based on the full market value of the property when it has been held for at least one year.

For information about these and other ways of making a gift to the Campaign, please contact:

Richard K. Naum
Vice President for Development
Memorial Sloan-Kettering Cancer Center
633 Third Avenue, 28th Floor
New York, NY 10017
646–227–3529 Telephone
646–227–3909 Fax
Memorial Sloan-Kettering Cancer Center’s commitment to conduct business in a sustainable way includes adopting green practices with respect to this report. This Annual Report is printed on Utopia One X: Green and is FSC-certified, contains a minimum of 20% post-consumer recovered fiber, and is manufactured with electricity in the form of renewable energy.

FSC is the Forest Stewardship Council, a nonprofit organization devoted to encouraging the responsible management of the world’s forests. FSC sets high standards that ensure forestry is practiced in an environmentally responsible, socially beneficial, and economically viable way.